Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (1):
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (7):
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82- . .
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
Grifols, S.A.
|
|
|
|
|
|
|
|
By:
|
/s/ David I. Bell
|
|
|
Name:
|
David I. Bell
|
|
|
Title:
|
Authorized Signatory
|
Date: July 29, 2021
First Half 2021 Results
The Bioscience Division
grows 5.1% in the
second quarter and raises first-half revenues
to EUR 2,537 million
Net income increased by 22% to EUR 267 million
•
|
Revenues in the second quarter grew 5.3% cc1 to EUR 1,352 million due to solid performance of the Bioscience, Diagnostic and Hospital Divisions.
|
|
|
•
|
Bioscience revenues increased 5.1% cc in the quarter and increase first-half revenues to EUR 1,986 million. Of note is the positive contribution of new products and the increase in prices of certain proteins.
|
|
|
•
|
The Diagnostic and Hospital Divisions recorded double-digit growth, attaining EUR 395 million (22.9% cc) and EUR 68 million (19.5% cc) in revenues, respectively.
|
|
|
•
|
EBITDA totals EUR 635 million (a 9.4% increase), 25.0% over sales.
|
|
|
•
|
Grifols’ financial debt ratio decreases to 4.9x. The strategic agreement with GIC will further reduce it by 0.6x.
|
|
|
•
|
Plasma collections in the U.S. continue to rise, while collections in Europe exceed pre-pandemic levels leveraging on recent acquisitions and multiple initiatives.
|
Barcelona,
July 29, 2021.- Grifols (MCE: GRF, MCE: GRF .P, NASDAQ: GRFS) reported 2.3% cc (-5.3% taking into account exchange rate
variations) growth and EUR 2,536.6 million in revenues in the first half, a period marked by the gradual recovery of plasma donations,
debt reduction, and significant investment efforts to further consolidate plasma supply levels and innovation.
In the second quarter of 2021, revenues
grew by 5.3% cc to EUR 1,351.9 million, fueled by the solid performance of the Bioscience, Diagnostic and Hospital divisions.
The Bioscience Division recorded notable
5.1% cc growth, reversing the 5.6% cc decline recorded in the first quarter. First-half revenues totaled EUR 1,986.0 million (-0.1% cc;
-8.0%).
1 Operating or constant currency (cc) excludes changes
rate variations reported in the period.
The division’s growth was driven
by robust demand for all major plasma proteins – immunoglobulins (IVIG and SCIG), albumin, alpha-1 and specialty proteins –
coupled with mid-single-digit price increases and the contribution of new products.
The Diagnostic
Division delivered EUR 395.5 million in sales in the first six months of 2021, growing by 22.9% cc (16.3%), mainly due to sales
of the TMA (Transcription-Mediated Amplification) molecular test to detect the SARS-CoV-2 virus, as well as underlying growth of NAT technology
(Procleix® NAT Solutions) solutions, used to screen whole blood and plasma.
Hospital
Division revenues increased for the third consecutive quarter as hospital investments and treatments normalize. The division registered
revenues of EUR 67.7 million in the first half, an operational increase of 19.5% cc (17.1%).
Bio
Supplies Division’s sales totaled EUR 107.3 million, a 8.5% cc decline (-15.4%) mainly as a result of lower third-party plasma
sales and Bio Supplies Commercial phasing.
The gross
margin in the first half was 43.9%, compared to 38.8% reported in the same period last year. The gross
margin for the second quarter stood at 43.0%.
EBITDA reached
EUR 634.5 million (EUR 337.7 million in the second quarter), a 9.4% increase during the first half. The EBITDA margin is 25.0% over revenues
(25.1% in the first quarter).
Grifols continues to execute its EUR 100
million per year operating expense containment plan, enabling the company to optimize its financial performance without impacting on its
innovation efforts.
Throughout the first six months of 2021,
Grifols has continued working on expanding its long-term plasma supply to meet current market needs and the anticipated robust demand.
Today, plasma collections in Europe exceed
2020 levels and pre-pandemic levels. U.S. plasma collections continue its upward trend. Currently, the capacity is 16.5 million liters
per year. Recent strategic acquisitions increased Grifols' plasma collection capacity, providing access to an additional 1.4 million liters
per year. In parallel, the company plans on opening 15 to 20 new centers in the second half of 2021.
The company reaffirmed its firm commitment
to innovation, combining its extensive experience in plasma-derived medicines while progressively developing a complementary portfolio
of non-plasma therapies. In this context, total net investment in R+D+i amounted to EUR 155.3 million,
representing 6.1% of revenues. These results underscore Grifols’ ongoing efforts to integrate and develop cutting-edge projects
as those of Alkahest and GigaGen.
Grifols allocated EUR
117.3 million (EUR 145.6 million in the first half of 2020) to CAPEX.
The financial
result in the first half of 2021 stood at EUR 119.4 million (EUR 132.4 million in the first half of 2020 excluding the positive
EUR 56.5 million impact from the closing of the Shanghai RAAS transaction registered in that period).
Share
of results of equity-accounted investees mainly includes the updated value of Grifols’ GigaGen stake (EUR 34.5 million),
following the agreement signed in the first quarter of 2021 to acquire the remaining capital.
The
reported net profit totaled EUR 266.8 million, a 22.3% increase over the EUR 218.2 million recorded
in the same period of 2020. This figure includes part of the COVID-192 impact.
The adjusted net profit amounts to EUR 279.1 million.
Excluding
the impact of IFRS 163, the net financial debt
reached EUR 6,475.5 million. In recent quarters, the leverage ratio has increased due to strategic acquisitions totaling USD 1 billion
to secure plasma supply, reinforce innovation and support global expansion.
Decreasing leverage remains a priority
for the company. In the first half of 2021, Grifols reduced the net financial debt over EBITDA ratio to 4.9x, down from the 5.1x reported
until the first quarter of the year.
The GIC, the sovereign wealth fund
of Singapore, agreement will also further reduce leverage by 0.6x, since the capital will be allocated in full to repay senior debt. GIC
will become a long-term strategic investor for the next 30 years as a result of this transaction.
As of June 30, 2021, Grifols’
cash position totaled EUR 398 million, bringing its liquidity position to EUR 813 million.
The efforts to increase plasma capacity,
business optimization, global expansion, innovation and financial discipline leave Grifols well positioned to respond to current needs
and fulfill its commitments and growth strategy.
2
|
In the first half of 2020,
Grifols recognized an estimated impact of EUR 205 million for the entire 2020 financial year to adjust inventory value as a result of
COVID-19.
|
3
|
As of June 30, 2021, the impact
of IFRS 16 on total debts stands at EUR 783 million.
|
About the Strategic investment from GIC in Biomat
In line with Grifols’ commitment
to reduce its leverage levels, the company takes a step further and welcomes GIC as a strategic investor. Grifols’ leadership in
the manufacture of plasma-based medicines, extensive expertise in the expansion and management of plasma centers, market know-how, and
outstanding reputation were all key factors in GIC’s decision to invest in the company.
As previously
announced, Grifols S.A. has signed a corporate transaction by means of which an affiliate of GIC, the sovereign wealth fund of Singapore,
have entered into a definitive agreement under which GIC will invest US$990 million in Grifols’ wholly-owned US subsidiary Biomat
USA, Inc. (“Biomat”). In exchange, GIC will receive an aggregate of 10 Class B common shares of Biomat and 9 Class B common
shares of a newly-established sub-holding company (“Newco”). These common shares, which will represent directly and indirectly
an aggregate of 23.8% of the equity of Biomat, will be non-voting but will have annual preferential dividends of US$4,168,421.05 per share
of each of Biomat and Newco. Beginning with respect to 2023, holders of these shares may request, subject to certain limitations, the
redemption of up to one share of Biomat or Newco per year, as applicable, at a redemption price of $52,105,263.16 per share (the “redemption
price”), provided that following the 15th anniversary
of the closing of the transaction, holders may request redemption of up to all their then outstanding shares. The shares will have customary
liquidation preference rights (in an amount per share equal to the redemption price plus unpaid dividends) that would trigger in certain
circumstances, such as in the case of a liquidation, dissolution or winding up of Biomat, if Grifols ceases to control or have at least
a 75% voting interest in Biomat, or upon the exclusive licensing of all or substantially all intellectual property of Biomat. In addition,
in the event of a default in the payment of dividends or redemptions, there would among other things be monetary penalties or holders
of the shares could opt to exchange them for shares of Grifols S.A.
Biomat (together with its subsidiaries)
holds a plasma collection business with 296 plasma collection centers throughout the territory of the United States. Grifols will continue
to control all aspects of the day-to-day management of Biomat and, through a long-term plasma supply agreement, all plasma collected by
Biomat and its subsidiaries will continue to be supplied to Grifols for the further manufacturing of plasma derived products. Grifols
intends to apply all net proceeds from GIC’s investment to repay debt.
Investor contact:
Investor Relations and Sustainability
inversores@grifols.com
- investors@grifols.com
sostenibilidad@grifols. com - sustainability@grifols.com
Tel. +34 93 571 02 21
Media contacts:
Raquel Lumbreras
|
|
Raquel_lumbreras@duomocomunicacion.com
|
Grifols
|
Borja Gómez
|
Media Press Office
|
Borja_gomez@duomocomunicacion.com
|
media@grifols.com
|
Duomo Comunicación – Grifols Press Office
|
Tel. +34 571 00 02
|
Tel. +34 91 311 92 89 - 91 311 92 90
|
|
+34 659 57 21 85 / +34 650 40 22 25
|
|
About Grifols
Grifols is a global healthcare company
founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience,
Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries.
Pioneers in the plasma industry, Grifols
operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic
and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio
of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services
that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.
Grifols, with close to 24,000 employees
in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical
leadership.
In 2020, Grifols’ economic impact
in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs.
The company’s class A shares are
listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the
Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).
For more information about Grifols, please visit
www.grifols.com
LEGAL DISCLAIMER
The facts and figures
contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions
such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”,
“should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions,
in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the
assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject
to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be
affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products,
the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among
others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of
these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt
them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation.
This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following
Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law
5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document
does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or
a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed
by the external auditors of the Grifols group.
|
Grifols
2021 Half Year Results
July 29, 2021
|
|
- 2 - First Half 2021 Results
IMPORTANT INFORMATION
This presentation does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of the Spanish Securities
Market Law (Royal Legislative Decree 4/2015, of 23 October, as amended and restated from time to time), Royal Decree 1310/2005, of November 4,
and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of
purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction.
FORWARD-LOOKING STATEMENTS
This presentation contains forward-looking information and statements about GRIFOLS based on current assumptions and forecast made by
GRIFOLS management, including pro forma figures, estimates and their underlying assumptions, statements regarding plans, objectives and
expectations with respect to capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking
statements are statements that are not historical facts and are generally identified by the words “expected”, “potential”, “estimates” and similar
expressions.
Although GRIFOLS believes that the expectations reflected in such forward-looking statements are reasonable, various known and unknown risks,
uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of
the Company and the estimates given here. These factors include those discussed in our public reports filed with the Comisión Nacional del Mercado
de Valores and the Securities and Exchange Commission, which are accessible to the public. The Company assumes no liability whatsoever to update
these forward-looking statements or conform them to future events or developments. Forward-looking statements are not guarantees of future
performance. They have not been reviewed by the auditors of GRIFOLS.
NON-GAAP FINANCIAL MEASURES
This presentation refers to certain non-GAAP financial measures. The presentation of these financial measures is not intended to be considered in
isolation, or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Investors are cautioned that
there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In addition, these measures may be
different from non-GAAP financial measures used by other companies, limiting their usefulness for comparative purposes. We compensate for these
limitations by providing specific information regarding GAAP amounts excluded from these non-GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in our Grifols
Condensed Consolidated Interim Financial Statements.
Disclaimer
|
|
First Half 2021 Results
We are growing global healthcare company
dedicated to improving people’s health and
well-being for more than 110 years
OUR MISSION
Bioscience
Global pioneer in the
production of essential
plasma-derived
therapies
Diagnostic
A leader in transfusion
medicine, from
donation to transfusion
Hospital
Advances in pharmacy
specialty products for
hospital use
Bio Supplies
Provider of biological
products for
non-therapeutic use
78% of revenues
15% of revenues
3% of revenues
4% of revenues
Note: % of revenues corresponds to HY 2021
4 Divisions
|
|
First Half 2021 Results
FOUR PILLARS DRIVE OUR OPERATIONS
Innovation Plasma Supply Industrial Excellence Global Expansion
Operations in 100+ countries
Subsidiaries in 30+ countries
x2.4
Immunology
Hepatology
Pulmonology
Hematology
Ophthalmology & Others
Infectious Diseases
Neurology
beyond plasma-derived products
in diverse therapeutic areas Evolution of plasma centers
47 1 296 7
150 159 171 190
221
295 312
351
centers via Shanghai
RAAS, including
2 under construction
41 20
new centers to be opened by
2023 in collaboration with the
Egyptian government
8.6
13.9 14.2 14.4
17.1
2014 2016 2018 2020 2021
Millions of liters x2.0
Global Market Share
IG
24%
Alpha-1
68%
Albumin
16%
FVIII
15%
Fractionation capacity
|
|
First Half 2021 Results
59
205
2016 2017 2018 2019 2020 LTM
Global presence with a diversified revenue base
Demonstrated ability to successfully grow businesses
both organically and through acquisitions
Vertically integrated business model
Leading player in plasma-derivatives industry with strong
fundamentals and a demonstrated resilience during
unprecedented times
Reinforced pipeline to deliver a risk-value balanced
portfolio
A focus on promoting countries’ plasma self-sufficiency
through new business models in countries including China,
Egypt and Canada
Commitment to increasing exposure of Bioscience and
Diagnostic in China
More than 5.1% growth over
the past 5 years
3,228
4,070
+5.1%
+7%
+4%
+41%
+4%
EUR M Revenues
INVESTMENT STRATEGY
664
831
99
129
Bioscience
Diagnostic
Bio Supplies
Hospital
Note: Graph not to scale. CAGR’s
|
|
Financial Results
|
|
- 7 - First Half 2021 Results
Highlights
Revenue Grows by 5.3% in Q2 with Sequential Upturns in EBITDA and Net
Profit
Performance in both H1 and Q2 demonstrates our ongoing
efforts to confront COVID-19-related challenges
Q2 strong 5.3% sales growth driven by Bioscience (5.1%),
Diagnostic (18.0%) and Hospital (36.6%)
Strong demand across key proteins backed by mid-single-
digit price increases
Contribution from new products represented c.5% of sales
Gross margin declined in Q2 due to higher cost per liter,
partially offset by positive product mix
EBITDA margin remains at 25%
R&D increases to 6.4% over revenues from 6.1% in
Q1 2021 as a result of innovation efforts
SG&A drops to 18.5% over revenues from 21.7% in
Q1 2021 driven by savings plan
Note: Growth % at constant currency (cc), which excludes
exchange rate fluctuations period over period
(EUR in millions) Q2 2021 Q1 2021 H1 2021
Revenue 1,351.9 1,184.7 2,536.6
% Growth (cc*) +5.3% -0.9% +2.3%
Gross Margin 580.8 533.3 1,114.1
% Margin 43.0% 45.0% 43.9%
EBITDA 337.7 296.8 634.5
% Margin 25.0% 25.1% 25.0%
% Growth +9.4%
Group Profit 136.9 129.9 266.8
% Growth +22.3%
Adj. Group Profit 161.6 117.5 279.1
|
|
- 8 - First Half 2021 Results
Revenues by Division
Bioscience Diagnostic
Hospital Bio Supplies
IVIG sales performance impacted
by lower volumes of plasma
collections
SCIG continued to gain traction
Alpha-1 achieves low double-
digit growth in Q2
Albumin has strong growth in
China (positive temporary effect
due to commercial integration with
SRAAS) and the U.S.
Specialty proteins attain double-
digit growth in Q2 led by Hypers
COVID tests 66M in H1
Underlying NAT mid-
single digit growth
in H1
Driven by double-digit growth in
Pharmatech and IV Therapy
Impacted by lower whole
blood collections and Bio
Supplies Commercial
sales phasing
Note: Growth % at constant currency (cc), which excludes
exchange rate fluctuations period over period
(EUR in millions) Q2 2021 Q1 2021 H1 2021
Bioscience 1,084.7
+5.1%
901.3
-5.6%
1,986.0
-0.1%
Diagnostic 192.2
+18.0%
203.3
+28.0%
395.5
+22.9%
Hospital 36.5
+36.6%
31.2
+4.3%
67.7
+19.5%
Bio Supplies 24.5
-22.8%
27.0
+5.0%
51.5
-10.3%
Others & Intersegment (12.5) (7.4) (19.9)
Total excl. 3rd parties 1,325.4
+5.4%
1,155.4
-0.5%
2,480.8
+2.5%
Plasma sold to 3rd p. 26.5 29.3 55.8
Total incl. 3rd parties 1,351.9
+5.3%
1,184.7
-0.9%
2,536.6
+2.3%
|
|
- 9 - First Half 2021 Results
Revenues by Region
U.S. + Canada
Europe
ROW 20%
18%
62%
U.S. and Canada revenues driven by:
High single-digit growth of Albumin and
double-digit growth of Hypers
Alpha-1 quarter-on-quarter sales growth due to
higher patient enrollment in programs
Strong growth in Q2 of SCIG by leveraging an
accelerated patient and prescriber base
Double-digit growth in Donor Screening and
Pharmatech
IVIG lower volume partially offset by price increases
EU continues to grow supported by:
Double-digit growth of IVIG (Flebogamma®)
and Alpha-1
COVID testing
Double-digit growth of Pharmatech
ROW benefits from double-digit growth of Albumin,
especially in China and Latam
(EUR in millions) Q2 2021 Q1 2021 H1 2021
U.S. + Canada 833.6
-1.9%
743.3
-10.4%
1,576.9
-6.1%
E.U. 220.6
+24.9%
231.9
+16.6%
452.5
+20.5%
ROW 297.7
+17.1%
209.5
+27.6%
507.2
+21.3%
Total 1,351.9
+5.3%
1,184.7
-0.9%
2,536.6
+2.3%
Note: Growth % at constant currency (cc), which excludes
exchange rate fluctuations period over period
|
|
- 10 - First Half 2021 Results
Quarter-on-Quarter Uptick from 5.6% Drop in Q1 to Q2 5.1% Growth
Performance by Division: Bioscience
IG
Albumin
Alpha-1
Specialty Proteins
Demand remains strong across key proteins
Plasma-driven supply constraints for IVIG, offset by mid-single-digit price increases
Alpha-1, SCIG, albumin and hyperimmunes showing strong growth
New products contribution (Xembify®, Vistaseal™ and Tavlesse®)
Gross margin still impacted by high cost per liter as a result of higher donor compensation and under-
absorption of fixed costs
Plasma collection in Europe currently exceeds 2020 levels and pre-pandemic levels. In the U.S., donations continue
to rise
Launch in July 2021 of Plasbumin® albumin in China, our third brand launch in the country
[10-15%]
[15-20%]
[15-20%]
[50-55%]
Note: Growth % at constant currency (cc), which excludes
exchange rate fluctuations period over period First Half 2021 Results
|
|
- 11 - First Half 2021 Results
Strong Quarter Driven by COVID Tests and Growth in Underlying NAT
Demand
Performance by Division: Diagnostic
Donor Screening
Blood Typing Solutions
Recombinant Proteins
Others [5-10%]
[10-15%]
[15-20%]
[60-65%]
COVID-19 tests continue to contribute to revenues (66M EUR in H1), with double-digit growth in donor screening
Underlying NAT sales grow by mid-single digit in H1 2021
Blood-typing solutions achieve steady growth
Margins impacted by product mix
Note: Growth % at constant currency (cc), which excludes
exchange rate fluctuations period over period First Half 2021 Results
|
|
- 12 - First Half 2021 Results
Positive Impact of Normalization of Hospital Investments
Performance by Division: Hospital
Pharmatech
IV Therapy
Contract Manufacturing
Others [15-20%]
[10-15%]
[30-35%]
[35-40%] Positive growth thanks to the gradual normalization of hospital
investments
Pharmatech and IV therapy are again main drivers of H1 growth,
expanding by double digits
Positive EBITDA in Q1 and Q2 with sequential improvement thanks to
operational leverage
Decrease of third-party plasma sales
Performance by Division: Bio Supplies
Commercial
Plasma
Others [5-10%]
[35-40%]
[50-55%] Bio Supplies commercial grew by double digits in Q1 but fell
in Q2 due to blood collections phasing
Third-party plasma sales decline due to phasing
Note: Growth % at constant currency (cc), which excludes
exchange rate fluctuations period over period
|
|
- 13 - First Half 2021 Results
Deleveraging Remains a Key Priority
Balance Sheet, Cash Flow and Liquidity
5.1
4.9
4.3
Q1 2021 HY 2021 Pro-forma
considering
GIC transaction
-16% Cash & Cash
Equivalents
Operating
Cash Flow
Liquidity
Acquisitions
CAPEX
398
Leverage Ratio
Note: All figures in million EUR
813
339
117
492
|
|
- 14 - First Half 2021 Results
Perspectives for 2H 2021 and 2022
Underlying IG and key proteins demand to remain strong
Plasma collections to continue positive evolution by leveraging on recent acquisitions and other initiatives.
Monitoring potential impacts of developments at the southern U.S. border
Donor commitment compensation remained high. Cost per liter to decline as volumes increase and donor
commitment compensation to descend in the second half of 2021
Diagnostic growth will see impact of COVID (as per the license agreement) and Zika test sales project
ramp down. Underlying NAT technology to continue to grow as plasma and whole blood donations and
medical procedures increase
Hospital to benefit from normalization of hospital investments
Bio Supplies Division expected to rebound in 2H 2021 following phasing
Maintaining financial discipline backed by EUR 100m cost savings plan
Non-strategic assets divestiture
Continued efforts to priorization of projects and spearhead innovation and R&D to exploit future growth
opportunities
Deleveraging and securing liquidity remain key priorities. GIC strategic investment to close in 2H 2021,
subject to regulatory approvals (CFIUS)
|
|
- 15 - First Half 2021 Results
Acquisitions in 2021: Increase in Plasma Supply
Capacity by 1.4 M Liters per Year
32+ plasma
centers
+25
+7
Q1 2021
Q2 2021
7+ plasma
centers
20 plasma centers to be
operational between 2021-2023
2 plasma centers to be opened
between H2 2021 and 2022
1M L/year
Q1 2021
240,000L/year
As part of our
organic efforts, we
anticipate opening
15-20 new
plasma centers in
H2 2021
120,000 L/year
|
|
- 16 - First Half 2021 Results
Enhancing Our Innovation Strategy
Acquisition of GigaGen’s Remaining Stake
Rationale
The agreement aligns with Grifols’ R+D+i strategy, grounded on an integrated approach encompassing both
in-house projects and investee-led initiatives and advances its efforts to build a reinforced pipeline and
risk-value balanced portfolio
Grifols pays USD 90.5 million to acquire the remaining 56% share capital of GigaGen, a U.S.
biopharmaceutical company dedicated to the discovery and development of recombinant
biotherapeutic products
The first 44% stake was acquired in July 2017 for USD 35 million through Grifols Innovation and New
Technology (GIANT), which channels the group's investments in R+D+i companies and other related projects
Transaction
Overview
Contribution to
Grifols Pipeline
Gigagen:
5 programs in discovery phase in immunology
and infectious diseases, among others
GIGA 564 in oncology: anti-CTLA-4 drug
candidate
GIGA 2050 and 2070 for the treatment of
COVID-19. 2050 phase I trial to be the first-in-
human study evaluating recombinant
hyperimmune immunoglobins
|
|
Annexes
|
|
- 18 - First Half 2021 Results
Key Financial Figures
(1) Excludes non-recurring items, including COVID-19; amortization of deferred expenses associated to the refinancing, amortization of intangible assets related to acquisitions and IFRS 16.
In millions of euros except % and
EPS 1H 2021 1H 2020 % Var 2Q 2021 2Q 2020 % Var 1Q 2021 1Q 2020 % Var
NET REVENUES 2,536.6 2,677.3 (5.3%) 1,351.9 1,384.0 (2.3%) 1,184.7 1,293.3 (8.4%)
GROSS MARGIN 43.9% 38.8% 43.0% 32.3% 45.0% 45.7%
EBITDA REPORTED 634.5 579.9 9.4% 337.7 228.8 47.6% 296.8 351.1 (15.5%)
% Net revenues 25.0% 21.7% 25.0% 16.5% 25.1% 27.2%
GROUP PROFIT 266.8 218.2 22.3% 136.9 31.9 329.2% 129.9 186.4 (30.3%)
% Net revenues 10.5% 8.2% 10.1% 2.3% 11.0% 14.4%
ADJUSTED1 GROUP PROFIT 279.1 350.1 (20.3%) 161.6 197.0 (18.0%) 117.5 153.1 (23.3%)
% Net revenues 11.0% 13.1% 12.0% 14.2% 9.9% 11.8%
CAPEX 117.3 145.6 (19.4%) 65.7 85.4 (23.0%) 51.6 60.2 (14.4%)
R&D NET INVESTMENT 155.3 166.8 (6.9%) 84.6 83.5 1.3% 70.7 83.3 (15.1%)
EARNINGS PER SHARE (EPS)
REPORTED 0.39 0.32 22.3% 0.20 0.05 22.3% 0.19 0.27 (30.3%)
|
|
- 19 - First Half 2021 Results
Net Revenue by Division
* Constant currency (cc) excludes exchange rate fluctuations period over period
In thousands of euros 1H 2021 1H 2020 % Var % Var cc* 2Q 2021 2Q 2020 % Var % Var cc* 1Q 2021 1Q 2020 % Var % Var cc*
BIOSCIENCE 1,986,024 2,158,852 (8.0%) (0.1%) 1,084,747 1,118,910 (3.1%) 5.1% 901,277 1,039,942 (13.3%) (5.6%)
DIAGNOSTIC 395,483 340,012 16.3% 22.9% 192,214 172,136 11.7% 18.0% 203,269 167,876 21.1% 28.0%
HOSPITAL 67,750 57,863 17.1% 19.5% 36,543 27,188 34.4% 36.6% 31,207 30,675 1.7% 4.3%
BIO SUPPLIES 107,260 126,718 (15.4%) (8.5%) 50,960 62,579 (18.6%) (12.2%) 56,300 64,139 (12.2%) (4.9%)
OTHERS 15,488 18,657 (17.0%) (11.5%) 8,314 13,513 (38.5%) (34.5%) 7,174 5,144 39.5% 49.0%
INTERSEGMENTS (35,373) (24,761) 42.9% 51.7% (20,880) (10,304) 102.6% 116.5% (14,493) (14,457) 0.2% 5.6%
TOTAL 2,536,632 2,677,341 (5.3%) 2.3% 1,351,898 1,384,022 (2.3%) 5.3% 1,184,734 1,293,319 (8.4%) (0.9%)
In thousands of euros 1H 2021 1H 2020 % Var % Var cc* 2Q 2021 2Q 2020 % Var % Var cc* 1Q 2021 1Q 2020 % Var % Var cc*
BIOSCIENCE 1,986,024 2,158,852 (8.0%) (0.1%) 1,084,747 1,118,910 (3.1%) 5.1% 901,277 1,039,942 (13.3%) (5.6%)
DIAGNOSTIC 395,483 340,012 16.3% 22.9% 192,214 172,136 11.7% 18.0% 203,269 167,876 21.1% 28.0%
HOSPITAL 67,750 57,863 17.1% 19.5% 36,543 27,188 34.4% 36.6% 31,207 30,675 1.7% 4.3%
BIO SUPPLIES 51,462 61,041 (15.7%) (10.3%) 24,432 33,630 (27.4%) (22.8%) 27,030 27,412 (1.4%) 5.0%
OTHERS 15,488 18,657 (17.0%) (11.5%) 8,314 13,513 (38.5%) (34.5%) 7,174 5,144 39.5% 49.0%
INTERSEGMENTS (35,373) (24,761) 42.9% 51.7% (20,880) (10,304) 102.6% 116.5% (14,493) (14,457) 0.2% 5.6%
TOTAL (Excl. Plasma sales 3rd party) 2,480,834 2,611,664 (5.0%) 2.5% 1,325,370 1,355,073 (2.2%) 5.4% 1,155,464 1,256,592 (8.0%) (0.5%)
Plasma sales 3rd party 55,798 65,677 (15.0%) 26,528 28,949 (8.4%) 29,270 36,727 (20.3%)
TOTAL 2,536,632 2,677,341 (5.3%) 2.3% 1,351,898 1,384,022 (2.3%) 5.3% 1,184,734 1,293,319 (8.4%) (0.9%)
|
|
- 20 - First Half 2021 Results
Net Revenue by Region
In thousands of euros 1H 2021 1H 2020 % Var % Var cc* 2Q 2021 2Q 2020 % Var % Var cc* 1Q 2021 1Q 2020 % Var % Var cc*
US + CANADA 1,576,893 1,844,576 (14.5%) (6.1%) 833,601 932,425 (10.6%) (1.9%) 743,292 912,151 (18.5%) (10.4%)
EU 452,536 376,442 20.2% 20.5% 220,598 176,843 24.7% 24.9% 231,938 199,599 16.2% 16.6%
ROW 507,203 456,323 11.1% 21.3% 297,699 274,754 8.4% 17.1% 209,504 181,569 15.4% 27.6%
TOTAL 2,536,632 2,677,341 (5.3%) 2.3% 1,351,898 1,384,022 (2.3%) 5.3% 1,184,734 1,293,319 (8.4%) (0.9%)
* Constant currency (cc) excludes exchange rate fluctuations period over period
|
|
- 21 - First Half 2021 Results
Profit and Loss
In thousands of euros 1H 2021 1H 2020 % Var 2Q 2021 2Q 2020 % Var 1Q 2021 1Q 2020 % Var
NET REVENUES 2,536,632 2,677,341 (5.3%) 1,351,898 1,384,022 (2.3%) 1,184,734 1,293,319 (8.4%)
COST OF SALES (1,422,509) (1,638,723) (13.2%) (771,102) (936,638) (17.7%) (651,407) (702,085) (7.2%)
GROSS MARGIN 1,114,123 1,038,618 7.3% 580,796 447,384 29.8% 533,327 591,234 (9.8%)
% Net revenues 43.9% 38.8% 43.0% 32.3% 45.0% 45.7%
R&D (158,542) (142,113) 11.6% (86,732) (74,248) 16.8% (71,810) (67,865) 5.8%
SG&A (507,002) (484,367) 4.7% (249,861) (233,781) 6.9% (257,141) (250,586) 2.6%
OPERATING EXPENSES (665,544) (626,480) 6.2% (336,593) (308,029) 9.3% (328,951) (318,451) 3.3%
SHARE OF RESULTS OF EQUITY ACCOUNTED INVESTEES
- CORE ACTIVITIES 14,971 9,558 56.6% 6,394 8,769 (27.1%) 8,577 789 987.1%
OPERATING RESULT (EBIT) 463,550 421,696 9.9% 250,597 148,124 69.2% 212,953 273,572 (22.2%)
% Net revenues 18.3% 15.8% 18.5% 10.7% 18.0% 21.2%
FINANCIAL RESULT (119,437) (75,929) 57.3% (60,737) (59,083) 2.8% (58,700) (16,846) 248.5%
SHARE OF RESULTS OF EQUITY ACCOUNTED INVESTEES 34,122 (18,622) (283.2%) (359) (13,172) (97.3%) 34,481 (5,450) (732.7%)
PROFIT BEFORE TAX 378,235 327,145 15.6% 189,501 75,869 149.8% 188,734 251,276 (24.9%)
% Net revenues 14.9% 12.2% 14.0% 5.5% 15.9% 19.4%
INCOME TAX EXPENSE (75,647) (65,469) 15.5% (37,900) (17,733) 113.7% (37,747) (47,736) (20.9%)
% of pre-tax income 20.0% 20.0% 20.0% 23.4% 20.0% 19.0%
CONSOLIDATED PROFIT 302,588 261,676 15.6% 151,601 58,136 160.8% 150,987 203,540 (25.8%)
RESULT ATTRIBUTABLE TO NON-CONTROLLING
INTERESTS 35,773 43,429 (17.6%) 14,721 26,269 (44.0%) 21,052 17,160 22.7%
GROUP PROFIT 266,815 218,247 22.3% 136,880 31,867 329.5% 129,935 186,380 (30.3%)
% Net revenues 10.5% 8.2% 10.1% 2.3% 11.0% 14.4%
|
|
- 22 - First Half 2021 Results
Group Profit Reconciliation
In millions of euros 1H 2021 1H 2020 % Var 2Q 2021 2Q 2020 % Var 1Q 2021 1Q 2020 % Var
GROUP PROFIT 266.8 218.2 22.3% 136.9 31.8 329.2% 129.9 186.4 (30.3%)
% Net revenues 10.5% 8.2% 10.1% 8.2% 11.0% 14.4%
Amortization of deferred financial expenses 25.6 23.0 11.3% 13.0 12.3 5.7% 12.6 10.7 17.8%
Amortization of intangible assets acquired in business
combinations 23.4 24.2 (3.3%) 11.8 12.9 (8.5%) 11.6 11.3 2.7%
Non-recurring items (34.5) (74.9) (53.9%) 1.0 (18.4) (105.4%) (35.5) (56.5) (37.2%)
IFRS 16 11.1 11.8 (5.9%) 5.7 5.7 0.0% 5.4 6.1 (11.5%)
Tax impacts (13.3) (7.0) 90.0% (6.8) (2.1) 223.8% (6.5) (4.9) 32.7%
COVID-19 impact - 185.3 - 185.3 --
Tax impacts COVID-19 impacts -(30.5)-(30.5) --
ADJUSTED GROUP NET PROFIT 279.1 350.1 (20.3%) 161.6 197.0 (18.0%) 117.5 153.1 (23.3%)
% Net revenues 11.0% 13.1% 12.0% 13.1% 9.9% 11.8%
|
|
- 23 - First Half 2021 Results
Cash Flow
In thousands of euros 1H 2021 1H 2020
REPORTED GROUP PROFIT 266,815 218,247
DEPRECIATION AND AMORTIZATION 166,754 158,216
NET PROVISIONS 562 (16,947)
OTHER ADJUSTMENTS AND OTHER CHANGES IN WORKING CAPITAL 143,088 50,242
CHANGES IN INVENTORIES (65,878) 250,879
CHANGES IN TRADE RECEIVABLES (142,672) (80,811)
CHANGES IN TRADE PAYABLES (29,367) (39,116)
CHANGE IN OPERATING WORKING CAPITAL (237,917) 130,952
NET CASH FLOW FROM OPERATING ACTIVITIES 339,302 540,710
BUSINESS COMBINATIONS AND INVESTMENTS IN GROUP COMPANIES (492,249) (21,802)
CAPEX (117,298) (145,572)
R&D/OTHER INTANGIBLE ASSETS (15,323) (37,466)
OTHER CASH INFLOW / (OUTFLOW) 1,508 (18,223)
NET CASH FLOW FROM INVESTING ACTIVITIES (623,362) (223,063)
FREE CASH FLOW (284,060) 317,647
PROCEEDS FROM / (PAYMENTS) FOR EQUITY INSTRUMENTS (125,703) -
ISSUE / (REPAYMENT) OF DEBT 467,002 (171,791)
DIVIDENDS (PAID) / RECEIVED (256,539) 1,790
OTHER CASH FLOWS FROM/(USED IN) FINANCING ACTIVITIES 350 (8,416)
NET CASH FLOW FROM FINANCING ACTIVITIES 85,110 (178,417)
TOTAL CASH FLOW (198,950) 139,230
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR 579,647 741,982
EFFECT OF EXCHANGE RATE CHANGES IN CASH AND CASH EQUIVALENTS 17,167 (2,806)
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 397,864 878,406
|
|
- 24 - First Half 2021 Results
Balance Sheet
ASSETS
In thousands of euros June December
2021 2020
NON-CURRENT ASSETS 12,973,549 12,109,822
GOODWILL AND OTHER INTANGIBLE ASSETS 8,278,506 7,568,617
PROPERTY PLANT & EQUIPMENT 2,415,934 2,324,107
INVESTMENTS IN EQUITY ACCOUNTED INVESTEES 1,904,321 1,869,020
NON-CURRENT FINANCIAL ASSETS 232,643 198,157
OTHER NON-CURRENT ASSETS 142,145 149,921
CURRENT ASSETS 3,239,500 3,164,954
INVENTORIES 2,124,393 2,002,281
TRADE AND OTHER RECEIVABLES 644,698 520,158
OTHER CURRENT FINANCIAL ASSETS 9,681 11,118
OTHER CURRENT ASSETS 62,864 51,750
CASH AND CASH EQUIVALENTS 397,864 579,647
TOTAL ASSETS 16,213,049 15,274,776
EQUITY AND LIABILITIES
In thousands of euros June December
2021 2020
EQUITY 6,937,091 6,720,055
CAPITAL 119,604 119,604
SHARE PREMIUM 910,728 910,728
RESERVES 4,138,199 3,776,932
TREASURY STOCK (164,189) (43,734)
CURRENT YEAR EARNINGS 266,815 618,546
OTHER COMPREHENSIVE INCOME (102,991) (273,684)
NON-CONTROLLING INTERESTS 1,768,925 1,611,663
NON-CURRENT LIABILITIES 7,354,480 7,219,583
NON-CURRENT FINANCIAL LIABILITIES 6,715,482 6,602,100
OTHER NON-CURRENT LIABILITIES 638,998 617,483
CURRENT LIABILITIES 1,921,478 1,335,138
CURRENT FINANCIAL LIABILITIES 940,906 424,612
OTHER CURRENT LIABILITIES 980,572 910,526
TOTAL EQUITY AND LIABILITIES 16,213,049 15,274,776
|
|
First Half 2021 Results
Grifols Contact
Investor Relations & Sustainability
+34 93 571 02 21
inversores@grifols.com
sostenibilidad@grifols.com
investors@grifols.com
sustainability@grifols.com
|
|
AFTER THIS PAGE IN DOC - ADD THE NEXT
2 PDF PAGES
|
|
GRIFOLS, S.A. and Subsidiaries
Notes to Condensed Consolidated Interim Financial Statements for the
six-month period ended 30 June 2021
CONTENTS
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language
version prevails)
I
Condensed Consolidated Interim Financial Statements
Balance Sheet
Statement of Profit or Loss
Statement of Comprehensive Income
Statement of Cash Flows
Statement of Changes in Equity
Notes to Condensed Consolidated Interim Financial Statements
(1) General Information
(2) Basis of Presentation and Accounting Principles Applied
(3) Changes in the composition of the Group
(4) Financial Risk Management Policy
(5) Segment Reporting
(6) Goodwill
(7) Other Intangible Assets and Property, Plant and Equipment
(8) Leases
(9) Equity-accounted investees
(10) Financial Assets
(11) Trade and Other Receivables
(12) Equity
(13) Financial Liabilities
(14) Expenses by Nature
(15) Finance Result
(16) Taxation
(17) Discontinued Operations
(18) Contingencies and Commitments
(19) Financial Instruments
(20) Related Parties
|
|
Assets 30/06/2021 31/12/2020
(unaudited)
Non-current assets
Goodwill (note 6) 5,988,765 5,332,271
Other intangible assets (note 7) 1,570,576 1,557,650
Rights of use (note 7 and 8) 719,165 678,696
Property, plant and equipment (note 7) 0 2,415,934 2,324,107
Investments in equity accounted investees (note 9) 1,904,321 1,869,020
Non-current financial assets (note 10)
Non-current financial assets measured at fair value 1,947 3,008
Non-current financial assets not measured at fair value 230,696 195,149
Deferred tax assets 0 142,145 149,921
Total non-current assets 0 12,973,549 12,109,822
Current assets
Inventories 0 2,124,393 2,002,281
Trade and other receivables 0
Trade receivables (note 11) 531,782 383,233
Other receivables (note 11) 79,782 72,360
Current income tax assets 33,134 64,565
Trade and other receivables 644,698 520,158
Other current financial assets (note 10) 0
Current financial assets not measured at fair value 9,681 11,118
Other current assets 62,864 51,750
Cash and cash equivalents 0 397,864 579,647
Total current assets 0 3,239,500 3,164,954
Total assets 0 16,213,049 15,274,776
The accompanying notes form an integral part of the unaudited condensed consolidated interim financial statements.
at 30 June 2021 and 31 December 2020
GRIFOLS, S.A. AND SUBSIDIARIES
(Expressed in thousands of Euros)
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)
Condensed Consolidated Balance Sheets
|
|
Equity and liabilities 30/06/2021 31/12/2020
(unaudited)
Equity
Share capital (note 12) 0 119,604 119,604
Share premium 0 910,728 910,728
Reserves (note 12) 0 4,138,199 3,776,932
Treasury stock (note 12) (164,189) (43,734)
Profit attributable to the Parent 0 266,815 618,546
Total 5,271,157 5,382,076
Other comprehensive Income (1,155) (1,155)
Translation differences (101,836) (272,529)
Other comprehensive expenses 0 (102,991) (273,684)
Equity attributable to the Parent 5,168,166 5,108,392
Non-controlling interests 0 1,768,925 1,611,663
Total equity 0 6,937,091 6,720,055
Liabilities
Non-current liabilities
Grants 16,933 17,008
Provisions 25,761 27,271
Non-current financial liabilities (note 13) 0 6,715,482 6,602,100
Other non-current liablities 16,767 16,391
Deferred tax liabilities 0 579,537 556,813
Total non-current liabilities 0 7,354,480 7,219,583
Current liabilities
Provisions 11,840 11,175
Current financial liabilities (note 13) 0 940,906 424,612
Trade and other payables 0
Suppliers 580,247 601,618
Other payables 177,321 141,089
Current income tax liabilities 29,535 3,482
Total trade and other payables 787,103 746,189
Other current liabilities 0 181,629 153,162
Total current liabilities 0 1,921,478 1,335,138
Total liabilities 9,275,958 8,554,721
Total equity and liabilities 0 16,213,049 15,274,776
The accompanying notes form an integral part of the unaudited condensed consolidated interim financial statements.
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)
GRIFOLS, S.A. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
at 30 June 2021 and 31 December 2020
(Expressed in thousands of Euros)
|
|
30/06/2021 30/06/2020 30/06/2021 30/06/2020
(unaudited) (unaudited) (unaudited)/
(not reviewed)
(unaudited)/
(not reviewed)
Continuing Operations
Net revenues (note 5) 2,536,632 2,677,341 1,351,898 1,384,022
Cost of sales (1,422,509) (1,638,723) (771,102) (936,638)
Gross Margin 1,114,123 1,038,618 580,796 447,384
Research and Development (158,542) (142,113) (86,732) (74,248)
Selling, general and administration expenses (507,002) (484,367) (249,861) (233,781)
Operating Expenses (665,544) (626,480) (336,593) (308,029)
Profit/(loss) of equity accounted investees with similar
activity to that of the Group 14,971 9,558 6,394 8,769
Operating Results 463,550 421,696 250,597 148,124
Finance income 4,949 4,580 1,804 1,982
Finance costs (119,698) (126,280) (61,061) (61,726)
Change in fair value of financial instruments 555 56,526 -- --
Exchange differences (5,243) (10,755) (1,480) 661
Finance Result (note 15) (119,437) (75,929) (60,737) (59,083)
Share of income/(losses) of equity accounted investees
34,122 (18,622) (359) (13,172)
Profit before income tax from continuing operations 378,235 327,145 189,501 75,869
Income tax expense (note 16) (75,647) (65,469) (37,900) (17,733)
Profit after income tax from continuing operations 302,588 261,676 151,601 58,136
Consolidated profit for the period 302,588 261,676 151,601 58,136
Profit attributable to the Parent 266,815 218,247 136,880 31,867
Profit attributable to non-controlling interest 35,773 43,429 14,721 26,269
Basic earnings per share (Euros) 0.39 0.32 0.20 0.05
Diluted earnings per share (Euros) 0.39 0.32 0.20 0.05
The accompanying notes form an integral part of the unaudited condensed consolidated interim financial statements.
GRIFOLS, S.A. AND SUBSIDIARIES
Condensed Consolidated Statements of Profit and Loss
for each of the three-and six-month periods ended 30 June 2021 and 2020
(Expressed in thousands of Euros)
Six-Months Ended Three-Months Ended
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)
|
|
30/06/2021 30/06/2020 30/06/2021 30/06/2020
(unaudited) (unaudited) (unaudited)/
(not reviewed)
(unaudited)/
(not reviewed)
Consolidated profit for the period 302,588 261,676 151,601 58,136
Items for reclassification to profit or loss
Translation differences 260,304 (54,982) (54,373) (221,154)
Equity accounted investees / Translation differences (note 9) 39,110 (17,214) 4,486 (19,235)
Other comprehensive income for the period, after tax 299,414 (72,196) (49,887) (240,389)
Total comprehensive income for the period 602,002 189,480 101,714 (182,253)
Total comprehensive income attributable to the Parent 437,508 139,448 99,145 (190,130)
164,494 50,032 2,569 7,877
Total comprehensive income for the period 602,002 189,480 101,714 (182,253)
The accompanying notes form an integral part of the unaudited condensed consolidated interim financial statements.
Condensed Consolidated Statements of Comprehensive Income
GRIFOLS, S.A. AND SUBSIDIARIES
Total comprehensive income attributable to non-controlling interests
Three-Months' Ended
for each of the three-and six-month periods ended 30 June 2021 and 2020
(Expressed in thousands of Euros)
Six-Months' Ended
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)
|
|
30/06/2021 30/06/2020
Cash flows from operating activities
Profit before tax 378,235 327,145
Adjustments for: 223,279 211,419
Amortisation and depreciation (note 14) 166,754 158,216
Other adjustments: 56,525 53,203
(Profit)/Losses on equity accounted investments (49,093) 9,064
Impairment of assets and net provision changes 562 (16,947)
Losses on disposal of fixed assets 172 32
Government grants taken to income (773) (663)
Finance cost 116,368 57,069
Other adjustments (10,711) 4,648
Changes operating assets and liabilities (179,678) 87,025
Change in inventories (65,878) 250,879
Change in trade and other receivables (146,904) (72,081)
Change in current financial assets and other current assets 4,565 (11,729)
Change in current trade and other payables 28,539 (80,044)
Other cash flows used in operating activities (82,534) (84,879)
Interest paid (71,286) (74,981)
Interest recovered 186 2,155
Income tax paid (9,679) (11,236)
Other amounts paid (1,755) (817)
Net cash from operating activities 339,302 540,710
Cash flows from investing activities
Payments for investments (625,152) (223,323)
Group companies and business combinations (492,249) (21,802)
Property, plant and equipment and intangible assets (132,621) (183,038)
Property, plant and equipment (103,522) (135,939)
Intangible assets (29,099) (47,099)
Other financial assets (282) (18,483)
Proceeds from 1,790 260
Property, plant and equipment and intangible assets 299 260
Other financial assets 1,491 0
Net cash used in investing activities (623,362) (223,063)
Cash flows from financing activities
Proceeds from and payments for equity instruments (125,703) 0
Acquisition of treasury stock (125,703) 0
Proceeds from and payments for financial liability intruments 467,002 (171,810)
Issue 675,760 108,116
Redemption and repayment (208,758) (279,926)
Dividends and interest on other equity instruments paid and received (256,539) 1,790
Dividends paid (258,945) 0
Dividends received 2,406 1,790
Other cash flows from financing activities 350 830
Financing costs included on the amortised costs of the debt 0 (9,227)
Net cash from (used in) financing activities 85,110 (178,417)
Effect of exchange rate fluctuations on cash and cash equivalents 17,167 (2,806)
Net increase/(decrease) in cash and cash equivalents (181,783) 136,424
Cash and cash equivalents at beginning of the period 579,647 741,982
Cash and cash equivalents at end of period 397,864 878,406
The accompanying notes form an integral part of the unaudited condensed consolidated interim financial statements.
for each of the six-month periods ended 30 June 2021 and 2020
GRIFOLS, S.A. AND SUBSIDIARIES
(unaudited)
Condensed Consolidated Statements of Cash Flows
(Expressed in thousands of Euros)
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)
|
|
Equity
Profit attributable attributable
Share Share to Interim Treasury Translation Other comprehensive to Non-controlling
capital premium Reserves Parent dividend stock differences income Parent interests Equity
Balances at 31 December 2019 119,604 910,728 3,009,599 625,146 (136,828) (49,584) 344,357 (903) 4,822,119 2,023,649 6,845,768
Translation differences -- -- -- -- -- -- (78,799) -- (78,799) 6,603 (72,196)
Other comprehensive income for the period 0 0 0 0 0 0 (78,799) 0 (78,799) 6,603 (72,196)
Profit/(loss) for the period -- -- -- 218,247 -- -- -- -- 218,247 43,429 261,676
Total comprehensive income for the period 0 0 0 218,247 0 0 (78,799) 0 139,448 50,032 189,480
Net change in treasury stock -- -- -- -- -- 5,814 -- -- 5,814 -- 5,814
Acquisition of non-controlling interests -- -- 408,675 -- -- -- -- -- 408,675 (408,675) 0
Other changes -- -- (11,115) -- -- -- -- -- (11,115) 10,829 (286)
Distribution of 2019 profit
Reserves -- -- 625,146 (625,146) -- -- -- -- 0 -- 0
Dividends -- -- -- -- -- -- -- -- 0 -- 0
Interim dividend -- -- -- -- -- -- -- -- 0 -- 0
Operations with equity holders or owners 0 0 1,022,706 (625,146) 0 5,814 0 0 403,374 (397,846) 5,528
Balances at 30 June 2020 (unaudited) 119,604 910,728 4,032,305 218,247 (136,828) (43,770) 265,558 (903) 5,364,941 1,675,835 7,040,776
Balances at 31 December 2020 119,604 910,728 3,776,932 618,546 0 (43,734) (272,529) (1,155) 5,108,392 1,611,663 6,720,055
Translation differences -- -- -- -- -- -- 170,693 -- 170,693 128,721 299,414
Other comprehensive income for the period 0 0 0 0 0 0 170,693 0 170,693 128,721 299,414
Profit/(loss) for the period -- -- -- 266,815 -- -- -- -- 266,815 35,773 302,588
Total comprehensive income for the period 0 0 0 266,815 0 0 170,693 0 437,508 164,494 602,002
Net change in treasury stock -- -- -- -- -- (120,455) -- -- (120,455) -- (120,455)
Acquisition of non-controlling interests -- -- 838 -- -- -- -- -- 838 (843) (5)
Other changes -- -- (5,674) -- -- -- -- -- (5,674) 113 (5,561)
Distribution of 2020 profit
Reserves -- -- 618,546 (618,546) -- -- -- -- 0 -- 0
Dividends -- -- (252,443) -- -- -- -- -- (252,443) (6,502) (258,945)
Interim dividend -- -- -- -- -- -- -- -- 0 -- 0
Operations with equity holders or owners 0 0 361,267 (618,546) 0 (120,455) 0 0 (377,734) (7,232) (384,966)
Balances at 30 June 2021 (unaudited) 119,604 910,728 4,138,199 266,815 0 (164,189) (101,836) (1,155) 5,168,166 1,768,925 6,937,091
Accumulated other comprehensive income
GRIFOLS, S.A. AND SUBSIDIARIES
Condensed Consolidated Statements of Changes in Equity
for each of the six-month periods ended 30 June 2021 and 2020
(Expressed in thousands of Euros)
Attributable to equity holders of the Parent
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
1
(1) General Information
Grifols, S.A. (hereinafter the Company) was incorporated with limited liability under Spanish law on 22 June
1987. Its registered and tax offices are in Barcelona. The Company's statutory activity consists of providing
corporate and business administrative, management and control services, as well as investing in assets and
property. Its principal activity involves rendering administrative, management and control services to its
subsidiaries.
On 17 May 2006 the Company completed its flotation on the Spanish securities market, which was conducted
through the public offering of 71,000,000 ordinary shares of Euros 0.50 par value each and a share premium of
Euros 3.90 per share. The total capital increase (including the share premium) amounted to Euros 312.4 million,
equivalent to a price of Euros 4.40 per share.
The Company’s shares were floated on the Spanish stock exchange IBEX-35 index on 2 January 2008.
All of the Company’s shares are listed on the Barcelona, Madrid, Valencia and Bilbao securities markets and on
the Spanish Automated Quotation System (SIBE/Continuous Market). On 2 June 2011, Class B non-voting shares
were listed on the NASDAQ (USA) and on the Spanish Automated Quotation System (SIBE/Continuous Market).
Grifols, S.A. is the Parent of the subsidiaries listed in Appendix I of the notes to the consolidated annual accounts
for the year ended 31 December 2020.
Grifols, S.A. and subsidiaries (hereinafter the Group) act on an integrated basis and under common management
and their principal activity is the procurement, manufacture, preparation and sale of therapeutic products,
especially hemoderivatives.
The main factory locations of the Group’s Spanish companies are in Parets del Vallés (Barcelona) and Torres de
Cotilla (Murcia), while the US companies are located in Los Angeles (California), Clayton (North Carolina),
Emeryville (California), and San Diego (California).
(2) Basis of Presentation and Accounting Principles Applied
These condensed consolidated interim financial statements for the six-month period ended 30 June 2021 have
been prepared under International Financial Reporting Standards as adopted by the European Union (IFRS-EU)
and specifically, with that provided by the guidelines of International Accounting Standard (hereinafter IAS) 34
on Interim Financial Reporting. They do not include all of the information required for full annual financial
statements and should be read in conjunction with the consolidated financial statements of the Group for the year
ended 31 December 2020.
The Board of Directors of Grifols, S.A. authorized these condensed consolidated interim financial statements for
issue at their meeting held on 28 July 2021.
Amounts contained in these condensed consolidated interim financial statements are expressed in thousands of
Euros.
The condensed consolidated interim financial statements of Grifols for the six-month period ended 30 June 2021
have been prepared based on the accounting records maintained by the Group. We also have included for
information purposes the three-month period ended 30 June 2021.
Accounting principles and basis of consolidation applied
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
2
Except as noted below, the accounting principles and basis of consolidation applied in the preparation of these
condensed consolidated interim financial statements are the same as those applied by the Group in its consolidated
annual accounts as at and for the year ended 31 December 2020.
In addition, in 2021 the following standards issued by the IASB and the IFRS Interpretations Committee, and
adopted by the European Union for their application in Europe have become effective and, accordingly, have
been taken into account for the preparation of these condensed consolidated interim financial statements:
The application of these standards and interpretations has not had any significant impacts on these condensed
consolidated interim financial statements.
At the date these condensed consolidated interim financial statements were authorized for issue, the following
IFRS standards, amendments and IFRIC interpretations have been issued by the European Union but their
application is not mandatory until future periods as described below:
Standards EU effective date IASB effective date
IFRS 4 Amendments to IFRS 4 Insurance Contracts -
deferral of IFRS 9 (issued on 25 June 2020) 1 January 2021 1 January 2021
Various
Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4
and IFRS 16 Interest Rate Benchmark Reform -
Phase 2 (issued on 27 August 2020)
1 January 2021 1 January 2021
Mandatory application for annual periods beginning on
or after:
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
3
The Group has not applied any of the standards or interpretations issued prior to their effective date.
Responsibility regarding information, estimates, and relevant judgments in the application of accounting
policies
The information contained in these condensed consolidated interim financial statements for the six-month period
ended 30 June 2021 is the responsibility of the Directors of the Company. The preparation of the condensed
consolidated interim financial statements requires management to make judgements, estimates and assumptions
that affect the application of Group accounting policies. The following notes include a summary of the relevant
accounting estimates and judgements used to apply accounting policies which have the most significant effect on
the amounts recognized in these condensed consolidated interim financial statements.
Assumptions used to test non-current assets and goodwill for impairment. Relevant cash generating
units are tested annually for impairment or when there is evidence that impairment could exist. These
are based on risk-adjusted future cash flows discounted using appropriate interest rates. Assumptions
Standards EU effective date IASB effective date
IFRS 17
Insurance Contracts (issued on 18 May 2017);
including Amendments to IFRS 17 (issued on 25
June 2020)
pending 1 January 2023
IAS 1
Amendments to IAS 1 Presentation of Financial
Statements: Classification of Liabilities as
Current or Non-current and Classification of
Liabilities asCurrent or Non-current - Deferral of
Effective Date (issued on 23 January 2020 and
15 July 2020 respectively).
pending 1 January 2023
IAS 1
Amendments issued 12 February 2021 to:
- IAS 1 Presentation of Financial Statements ;
- IFRS Practice Statement 2: Disclosure of
Accounting policies
pending 1 January 2023
IAS 8
Amendments to IAS 8 Accounting policies,
Changes in Accounting Estimates and Errors:
Definition of Accounting Estitmates (issued on
12 February 2021)
pending 1 January 2023
IFRS 16
Amendment to IFRS 16 Leases Covid 19-Related
Rent Concessions beyond 30 June 2021 (issued
on 31 March 2021)
pending 1 April 2021
IAS 12
Amendments to IAS 12 Income Taxes: Deferred
Tax related to Assets and Liabilities arising from
a Single Transaction (issued on 7 May 2021)
pending 1 January 2023
Various
Amendments issued 14 May 2020 to:
- IFRS 3 Business Combinations: references to
the Conceptual Framework;
- IAS 16 Property, Plant and Equipment:
Proceeds before Intended Use;
- IAS 37 Provisions, Contingent Liabilities and
Contingent Assets: Onerous Contracts - Cost of
Fulfilling a Contract ; and
- Annual Improvements to IFRSs 2018-2020:
IFRS 1, IFRS 9, IFRS 16 and IAS 41.
1 January 2022 1 January 2022
Mandatory application for annual periods beginning on
or after:
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
4
relating to risk-adjusted future cash flows and discount rates are based on business forecasts and are
therefore inherently subjective. Future events could cause a change in business forecasts, with a
consequent adverse effect on the future results of the Group. To the extent considered that a reasonably
possible change in key assumptions could result in impairment of goodwill, a sensitivity analysis has
been disclosed in note 6.
Determination of the fair value of assets, liabilities and contingent liabilities related to business
combinations.
Evaluation of the capitalization of development costs. The key assumption is related to the estimation
of sufficient future economic benefits of the projects.
Evaluation of provisions and contingencies. Key assumptions relate to the evaluation of the likelihood
of an outflow of resources due to a past event, as well as to the evaluation of the best estimate of the
likely outcome. These estimates take into account the specific circumstances of each dispute and
relevant external advice and therefore are inherently subjective and could change substantially over time
as new facts arise and each dispute progresses. Details of the status of various uncertainties involved in
significant unresolved disputes are set out in note 18.
The calculation of the income tax expense requires tax legislation interpretations in the jurisdictions
where Grifols operates. The decision as to whether the taxation authorities will accept a given uncertain
tax treatment and the expected outcome of outstanding litigation requires significant estimates and
judgements. Likewise, Grifols recognizes deferred tax assets, mainly from deductible temporary
differences to the extent that it is probable that sufficient taxable income will be available against which
they can be utilized, based on management estimates on amount and payments of future taxable profits
(see notes 4(s) and 28 to the consolidated financial statements as at and for the year ended 31 December
2020).
Determination of chargebacks made to certain customers in the United States (see note 4 r in the
consolidated annual accounts for the year ended 31 December 2020).
No changes have been made to prior year judgements relating to existing uncertainties.
The Group is also exposed to interest rate and currency risks.
Grifols’ management does not consider that there are any assumptions or causes for uncertainty in the estimates
which could imply a significant risk of material adjustments arising in the next financial year.
The estimates and relevant judgments used in the preparation of these condensed consolidated interim financial
statements do not significantly differ from those applied in the preparation of the consolidated financial statements
as at and for the year ended 31 December 2020.
Seasonality of transactions during this period
Given the nature of the activities conducted by the Group, there are no factors that determine any significant
seasonality in the Group’s operations that could affect the interpretation of these condensed consolidated interim
financial statements for the six-month period ended 30 June 2021 in comparison with the financial statements for
a full fiscal year.
Relative importance
When determining the information to be disclosed in these Notes, in accordance with IAS 34, the relative
importance in relation to these condensed consolidated interim financial statements has been taken into account.
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
5
(3) Changes in the Composition of the Group
For the preparation of its condensed consolidated interim financial statements, the Group has included its
investments in all subsidiaries, associates and joint ventures. Appendix I of the consolidated financial statements
as at 31 December 2020 lists the subsidiaries, associates and joint ventures in which Grifols, S.A. holds a direct
or indirect stake and that were included in the scope of consolidation at that date.
The main changes in the scope of consolidation during the interim period ended 30 June 2021 are detailed below:
BPL Plasma, Inc.
On 28 February 2021, Biomat USA, Inc., an american subsidiary of the Group, has acquired 25 plasma donation
centers in the United States from the company BPL Plasma, Inc., a subsidiary of Bio Products Laboratory
Holdings Limited, for an amount of US Dollars 385 million.
The transaction has received the applicable regulatory clearances and will be financed with Grifols’ own
resources, without issuing debt.
Grifols will obtain approximately 1 million liters of plasma per year from this centers.
The transaction costs have amounted to Euros 8,799 thousand and have been recognized as “operating expenses”
in the consolidated statement of profit and loss.
Details of the aggregate business combination cost, the fair value of the net assets acquired and the goodwill at
the acquisition date are provided below:
The amounts determined at the date of acquisition of assets, liabilities and contingent liabilities are as follows:
Thousands of Euros Thousands of US
Dollars
Cost of the business combination
First payment 9,921 12,000
Cash paid at transaction closing date 308,016 372,548
Total business combination cost 317,937 384,548
Fair value of net assets acquired 15,039 18,190
Goodwill (excess of the cost of the business combination over the fair
value of net assets acquired) (note 6) 302,898 366,358
Thousands of Euros Thousands of US
Dollars
Property, plant and equipment (note 7) 14,406 17,424
Non-current financial assets 85 103
Inventories 557 674
Total assets 15,048 18,201
Current liabilities (9) (11)
Total liabilities and contingent liabilities (9) (11)
Total net assets acquired 15,039 18,190
Fair value
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
6
The resulting goodwill has been allocated to the Bioscience segment, and it includes the donor data base, licenses
and workforce.
Acquisition of plasma centers from Kedplasma, LLC.
On 31 March 2021, Biomat USA, Inc., an american subsidiary of the Group, has acquired 7 plasma donation
centers in the United States from the company Kedplasma, LLC for an amount of US Dollars 55.2 million. All
the acquired centers are authorized by the U.S. Food and Drug Administration (FDA) and European healthcare
authorities.
Grifols will gain immediate access to the plasma obtained in these centers, which obtain approximately 240,000
liters per year.
The operation received regulatory clearances and will be financed with Grifols’ own resources, without issuing
debt.
The transaction costs have amounted to Euros 625 thousand and have been recognized as “operating expenses”
in the consolidated statement of profit and loss.
Details of the aggregate business combination cost, the fair value of the net assets acquired and the goodwill at
the acquisition date are provided below:
The amounts determined at the date of acquisition of assets, liabilities and contingent liabilities are as follows:
The resulting goodwill has been allocated to the Bioscience segment, and it includes the donor data base, licenses
and workforce.
Thousands of Euros Thousands of US
Dollars
Cost of the business combination
Cash paid 45,638 55,200
Total business combination cost 45,638 55,200
Fair value of net assets acquired 2,692 3,256
Goodwill (excess of the cost of the business combination over the fair
value of net assets acquired) (note 6) 42,946 51,944
Thousands of Euros Thousands of US
Dollars
Property, plant and equipment (note 7) 2,448 2,961
Inventories 244 295
Total assets 2,692 3,256
Total net assets acquired 2,692 3,256
Fair value
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
7
Gigagen, Inc.
On 8 March 2021, Grifols, through its 100% owned subsidiary Grifols Innovation and New Technologies Limites
(“GIANT”), signed an agreement to acquire all the shares of Gigagen, Inc. for a total amount of US Dollars 90.5
million.
GigaGen is a U.S. biotechnology company specialized in the early discovery and development of recombinant
biotherapeutic medicines. GigaGen’s research focuses on discovering new biological treatments based on
antibodies derived from millions of immune system cells obtained from donors.
With the acquisition of 100% shares, Grifols has control over Gigagen and, therefore, it is considered part of the
group and it has been fully consolidated. Until that date, the previous 43.96% stake was recorded using the equity
method. The difference between the fair value of the previous investment and the book value amounted to Euros
34,525 thousand (US Dollars 41,758 thousand) and has been recognized as income under “Profit/(loss) of equity
accounted investees” in the consolidated statement of profit and loss.
From the total agreed, on 30 June 2021 the Group has already paid an amount of Euros 37,576 thousand and there
is an amount payable of Euros 35,584 thousand presented under the line item “Current financial liabilities” with
due date March 2022.
Details of the aggregate business combination cost, the fair value of the net assets acquired and the provisional
goodwill at the acquisition date are provided below:
Thousand of Euros Thousand of US
Dollars
Cost of the business combination
First purchase of shares 38,201 46,203
Second purchase of shares (discounted amount) 35,227 42,608
Total business combination cost 73,428 88,811
Fair value of the previous investment in the company 50,792 61,434
Fair value of net assets acquired 1,461 1,767
Goodwill (excess of the cost of the business combination over the
fair value of net assets acquired) 122,759 148,478
The provisional amounts determined at the date of acquisition of assets, liabilities and contingent liabilities are as
follows:
Thousand of Euros Thousand of
US Dollars
Property, plant and equipment (note 7) 1,168 1,413
Other non current assets 151 183
Trade and other reeceivables 16 19
Other current assets 2,368 2,864
Cash and cash equivalents 12,389 14,985
Total assets 16,092 19,464
Non-current liabilities (4,247) (5,137)
Current liabilities (10,384) (12,560)
Total Liabilities (14,631) (17,697)
Fair value of net assets acquired 1,461 1,767
Fair Value
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
8
The profit of Gigagen between the acquisition date and 30 June 2021 amounted to Euros (3,822) thousand.
Green Cross
On 20 July 2020, Grifols signed share purchase arrangements with the South Korean based GC Pharma Group
and other investors for the acquisition of a plasma fractionation facility and two purification facilities located in
the city of Montreal, Canada, and 11 plasma collection centers located in the United States, for a total
consideration of Euros 387,917 thousand (US Dollars 457,160 thousand), on a debt free basis. On 1 October 2020,
the transaction was closed.
Details of the aggregate business combination cost, the fair value of the net assets acquired and the final goodwill
at the acquisition date are provided below:
The final amounts determined at the date of acquisition of assets, liabilities and contingent liabilities are as
follows:
Thousands of Euros Thousands of US
Dollars
Cost of the business combination
Cash paid 387,917 457,160
Total business combination cost 387,917 457,160
Fair value of net assets acquired 189,761 223,633
Goodwill (excess of the cost of the business
combination over the fair value of net assets acquired)
(note 6) 198,156 233,527
Thousand of Euros Thousand of
US Dollars
Other Intangible assets 2,011 2,370
Rights of Use 11,642 13,720
Property, plant and equipement 159,013 187,396
Deferred tax assets 28,615 33,724
Non-current assets 122 144
Inventories 2,999 3,534
Trade and other receivables 3,484 4,106
Other current assets 943 1,111
Cash and cash equivalents 6,053 7,133
Total assets 214,882 253,238
Non-current financial liabilities (13,150) (15,497)
Defererd Tax Liabilities -- --
Current financial liabilities (797) (939)
Trade and other payables (11,174) (13,169)
Total liabilities (25,121) (29,605)
Fair value of net assets acquired 189,761 223,633
Fair Value
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
9
(4) Financial Risk Management Policy
At 30 June 2021 the Group’s financial risk management objectives and policies are consistent with those disclosed
in the consolidated financial statements for the year ended 31 December 2020.
(5) Segment Reporting
The distribution by business segments of the Group’s net revenues for the three- and six-month periods ended 30
June 2021 and 30 June 2020 is as follows:
The distribution by geographical area of the Group’s net revenues for the three- and six-month periods ended 30
June 2021 and 30 June 2020 is as follows:
Segments
Six-Months Ended 30
June 2021
Six-Months Ended
30 June 2020
Three-Months
Ended 30 June 2021
Three-Months
Ended 30 June 2020
Not reviewed Not reviewed
Bioscience 1,986,024 2,158,852 1,084,747 1,118,910
Hospital 67,750 57,863 36,543 27,188
Diagnostic 395,483 340,012 192,214 172,136
Bio supplies 107,260 126,718 50,960 62,579
Other 15,488 18,657 8,314 13,513
Intersegments (35,373) (24,761) (20,880) (10,304)
Total Revenues 2,536,632 2,677,341 1,351,898 1,384,022
Net revenues (Thousands of Euros)
Geographical area
Six-Months
Ended 30 June
2021
Six-Months
Ended 30 June
2020
Three-Months
Ended 30 June
2021
Three-Months
Ended 30 June
2020
Not reviewed Not reviewed
Spain 180,509 128,614 85,671 59,072
Rest of the EU 272,027 247,828 134,927 117,771
USA + Canada 1,576,893 1,844,576 833,601 932,425
Rest of the World 507,203 456,323 297,699 274,754
Total Revenues 2,536,632 2,677,341 1,351,898 1,384,022
Net revenues (Thousands of Euros)
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
10
The distribution by business segments of the Group’s consolidated income for the three- and six-month periods
ended 30 June 2021 and 30 June 2020 is as follows:
Segments
Six-Months
Ended 30 June
2021
Six-Months
Ended 30 June
2020
Three-Months
Ended 30 June
2021
Three-Months
Ended 30 June
2020
Not reviewed Not reviewed
Bioscience 443,811 414,397 247,777 125,194
Hospital (3,577) (8,584) (771) (2,697)
Diagnostic 104,561 87,234 48,741 50,006
Bio supplies 23,312 8,374 11,540 1,936
Other 14,277 (5,976) (16,699) 6,804
Intersegments (11,762) 4,005 (8,831) 5,434
Total income of reported segments 570,622 499,450 281,757 186,677
Unallocated expenses plus net
financial result (192,387) (172,305) (92,256) (110,808)
Profit before income tax from
continuing operations 378,235 327,145 189,501 75,869
Profit/(loss) (Thousands of Euros)
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
11
(6) Goodwill
Details and movement in goodwill during the six-month period ended 30 June 2021 is as follows:
Impairment testing:
As a result of the acquisition of Talecris in 2011, and for impairment testing purposes, the Group combines the
CGUs allocated to the Bioscience segment, grouping them together at segment level, because substantial
synergies were expected to arise on the acquisition of Talecris, and due to the vertical integration of the business
and the lack of an independent organized market for the products. Because the synergies benefit the Bioscience
segment globally they cannot be allocated to individual CGUs. The Bioscience segment represents the lowest
level to which goodwill is allocated and is subject to control by Group management for internal control purposes.
As a result of the acquisition of Novartis’ Diagnostic business unit in 2014, the Group decided to combine
Araclon, Progenika, Australia and Hologic’s share of NAT donor screening unit acquisition into a single CGU
for the Diagnostic business as the acquisition is supporting not only the vertically integration business but also
cross-selling opportunities. In addition, for management purposes, the Group’s management is focused on the
business more than geographical areas or individual companies.
Balance at Business Translation Balance at
Segment 31/12/2020 Combination differences 30/06/2021
Net value
Grifols UK, Ltd. (UK) Bioscience 7,674 -- 333 8,007
Grifols Italia.S.p.A. (Italy) Bioscience 6,118 -- -- 6,118
Biomat USA, Inc.(USA) (see note 3) Bioscience 234,791 345,844 14,460 595,095
Grifols Australia Pty Ltd.
(Australia) / Medion Diagnostics AG
(Switzerland)
Diagnostic 9,538 -- (13) 9,525
Grifols Therapeutics, Inc. (USA) Bioscience 1,816,404 -- 57,911 1,874,315
Araclon Biotech, S.L. (Spain) Diagnostic 6,000 -- -- 6,000
Progenika Biopharma, S.A. (Spain) Diagnostic 40,516 -- -- 40,516
Grifols Diagnostic (Novartis & Hologic)
(USA, Spain and Hong Kong) Diagnostic 2,376,978 -- 74,996 2,451,974
Kiro Grifols, S.L. (Spain) Hospital 24,376 -- -- 24,376
Goetech, LLC. (USA) Hospital 55,167 -- 1,759 56,926
Haema, AG. (Germany) Bioscience 190,014 -- -- 190,014
BPC Plasma, Inc (USA) Bioscience 140,334 -- 4,473 144,807
Interstate Blood Bank, Inc. (USA) Bioscience 158,479 -- 5,053 163,532
Plasmavita Healthcare, GmbH (Germany) Bioscience 9,987 -- -- 9,987
Alkahest, Inc (USA) Others 71,910 -- 2,293 74,203
Grifols Canada Therapeutics, Inc (formerly
Green Cross Biotherapeutics, Inc.) (Canada)
(see note 3)
Bioscience 134,569 13,414 9,160 157,143
GCAM, Inc (formerly Green Cross America
Inc.) (USA) Bioscience 49,416 -- 1,576 50,992
GigaGen, Inc (USA) (see note 3) Others -- 122,759 2,476 125,235
5,332,271 482,017 174,477 5,988,765
Thousands of Euros
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
12
Due to the acquisition of an additional 40% stake in Kiro Grifols S.L. and a 51% stake in Goetech LLC
(Medkeeper), the Group decided to group Kiro Grifols S.L., Laboratorios Grifols S.A. and Medkeeper into a
single CGU for the Hospital business since the acquisitions are supporting cross-selling opportunities.
The CGUs established by Management are:
Bioscience
Diagnostic
Hospital
The COVID-19 pandemic has caused unprecedented turmoil in the global economy, the breadth and duration of
which remain unknown. While some industries and companies may be more vulnerable than others, the effects
of the pandemic have affected social and economic behavior, increasing the overall uncertainty.
Our products from Bioscience CGU are considered lifesaving and have been identified as a strategic industry for
most governments and therefore are prevented from being suspended. However, at the preparation date of the
financial statements, Grifols has estimated a temporary impact derived from COVID-19.
There are no indications of impairment in the Diagnostic CGU since new opportunities have arisen from COVID-
19 pandemic which have offset the potential negative impact deriving therefrom.
The recoverable amount of the Bioscience CGU and Hospital CGU has been calculated based on its value in use
calculated as the present value of the future cash flows discounted at a discount rate considering the related
inherent risk.
In the current uncertain environment, the recoverable amount calculations of the Bioscience and Hospital CGU
use expected cash flow projections for five and six years respectively based on two different scenarios considered
in respect of COVID-19 impact (base case and worst case) and the assigned weighting of these scenarios
according to the following details:
Management has determined the gross margin based on past experience and the current situation derived from
the COVID-19 pandemic, investments in progress which would imply significant growth in production capacity
and its forecast international market development.
Cash flows estimated as of the year in which stable growth in the CGU has been reached are extrapolated using
the estimated growth rates indicated below. Perpetual growth rates are consistent with the forecasts included in
industry reports.
The key assumptions used in calculating impairment testing of the CGUs for 2020 were as follows:
Perpetual Growth rate Discount Rate
Bioscience 1.9% 8.9%
Hospital 1.4% 10.8%
Assigned
weighting
Base case Total recovery in 2022 70% Total recovery in 2021 70%
Worst case Total recovery beyond
2022 30% Total recovery in 2022 30%
Bioscience CGU Hospital CGU
Main assumption Main assumption Assigned
weighting
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
13
The key assumptions used in calculating impairment testing of the CGUs for the six-month period ended 30 June
2021 have been as follows:
Perpetual Growth rate Discount Rate
Bioscience 2.0% 9.2%
Hospital 1.5% 10.8%
The discount rate used reflects specific risks relating to the CGUs and the countries in which they operate. The
main assumptions used for determining the discount rate are as follows:
Risk free rate: normalized government bonds at 10 years
Market risk premium: premium based on market research
Unlevered beta: average market beta
Debt to equity ratio: average market ratio
In 2020 and 2021, the reasonably possible changes considered for the Bioscience and Hospital CGUs are a
variation in the discount rate, as well as in the estimated perpetual growth rate, as follows:
Perpetual Growth rate Discount Rate
Bioscience +/- 50 bps +/- 50 bps
Hospital +/-100 bps +/-100 bps
The reasonably possible changes in key assumptions considered by management in the calculation of the
Bioscience CGU’s recoverable amount would not cause the carrying amount to exceed its recoverable amount.
The reasonably possible changes in key assumptions considered by management in the calculation of the Hospital
CGU’s recoverable amount would cause the carrying amount to exceed its recoverable amount as follows:
Discount Rate
+100 bps
Hospital 5.0%
At 30 June 2021 Grifols’ stock market capitalization totals Euros 13,602 million (Euros 14,207 million at 31
December 2020).
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
14
(7) Other Intangible Assets, Rights of Use and Property, Plant, and Equipment
Movement in other intangible assets, rights of use and property, plant and equipment during the six-month period
ended 30 June 2021 is as follows:
Other intangible
assets Rights of Use Property, plant and
equipment Total
Total Cost at 31/12/2020 2,370,373 787,407 3,685,191 6,842,971
Total depreciation and amortization at 31/12/2020 (747,594) (108,711) (1,358,431) (2,214,736)
Impairment at 31/12/2020 (65,129) -- (2,653) (67,782)
Balance at 31/12/2020 1,557,650 678,696 2,324,107 4,560,453
Cost
Additions 29,098 55,063 112,132 196,293
Business combination (note 3) -- -- 3,741 3,741
Disposals (12,184) (1,584) (13,075) (26,843)
Transfers 1,251 2,795 (3,035) 1,011
Translation differences 65,606 20,925 93,601 180,132
Total Cost at 30/06/2021 2,454,144 864,606 3,878,555 7,197,305
Depreciation & amortization
Additions (note 14) (51,088) (32,425) (83,241) (166,754)
Disposals 38 1,464 11,179 12,681
Transfers 611 (2,809) 1,188 (1,010)
Translation differences (18,458) (2,960) (30,695) (52,113)
Total depreciation and amortization at 30/06/2021 (816,491) (145,441) (1,460,000) (2,421,932)
Impairment
Additions -- -- 56 56
Translation differences (1,948) -- (24) (1,972)
Total impairment at 30/06/2021 (67,077) -- (2,621) (69,698)
Total balance at 30/06/2021 1,570,576 719,165 2,415,934 4,705,675
Thousands of Euros
At 30 June 2021 there are no indications that these assets have been impaired.
Intangible assets acquired from Talecris mainly include currently marketed products. Identifiable intangible assets
correspond to Gamunex and have been recognized at fair value at the acquisition date of Talecris and classified
as currently marketed products. Intangible assets recognized comprise the rights on the Gamunex product, its
commercialization and distribution license, trademark, as well as relations with hospitals. Each of these
components are closely linked and fully complementary, are subject to similar risks and have a similar regulatory
approval process.
Intangible assets acquired from Progenika mainly include currently marketed products. Identifiable intangible
assets correspond to blood, immunology and cardiovascular genotyping. These assets have been recognized at
fair value at the acquisition date of Progenika and classified as currently marketed products.
The cost and accumulated amortization of currently marketed products acquired from Talecris and Progenika at
30 June 2021 is as follows:
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
15
The estimated useful life of the currently marketed products acquired from Talecris is considered limited, has
been estimated at 30 years based on the expected life cycle of the product (Gamunex) and is amortized on a
straight-line basis.
At 30 June 2021 the residual useful life of currently marketed products from Talecris is 19 years and 11 months
(20 years and 11 months at 30 June 2020).
The estimated useful life of the currently marketed products acquired from Progenika is considered limited, has
been estimated at 10 years based on the expected life cycle of the product and is amortized on a straight-line basis.
At 30 June 2021 the residual useful life of currently marketed products from Progenika is 1 year and 8 months (2
years and 8 months at 30 June 2020).
(8) Leases
Details of leases at 30 June 2021 and 31 December 2020 are as follows:
Movement during the period ended 30 June 2021 is included in note 7 “Other intangible assets, rights of use and
property, plant and equipment”.
The amounts recognized in the consolidated statement of profit and loss related to lease agreements for the three-
month and six-month period ended 30 June 2020 and 2021 are as follows:
Balance at Translation Balance at
31/12/2020 Additions differences 30/06/2021
Cost of currently marketed products - Gamunex 980,873 -- 31,273 1,012,146
Cost of currently marketed products - Progenika 23,792 -- -- 23,792
Accumulated amortisation of currently marketed
products - Gamunex (313,335) (16,564) (10,294) (340,193)
Accumulated amortisation of currently marketed
products - Progenika (18,633) (1,190) -- (19,823)
Net carrying amount of currently marketed products 672,697 (17,754) 20,979 675,922
Thousands of Euros
Rights of use
30/06/2021 31/12/2020
Land and Buildings 706,063 665,002
Machinery 4,631 3,671
Computer equipment 2,567 3,588
Vehicles 5,904 6,435
719,165 678,696
Thousands of Euros
Lease liabilities
30/06/2021 31/12/2020
Non-current 737,830 690,857
Current 45,315 42,642
783,145 733,499
Thousands of Euros
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
16
Six-Months
Ended 30 June
2021
Six-Months
Ended 30 June
2020
Three-Months
Ended 30 June
2021
Three-Months
Ended 30 June
2020
Not reviewed Not reviewed
Finance lease expenses (note 15) 17,133 18,055 8,701 9,117
17,133 18,055 8,701 9,117
Thousands of Euros
Six-Months
Ended 30 June
2021
Six-Months
Ended 30 June
2020
Three-Months
Ended 30 June
2021
Three-Months
Ended 30 June
2020
Not reviewed Not reviewed
Expenses related to short-term agreements 2,404 1,792 1,194 345
Expenses related to low-value agreements 6,859 5,606 3,403 2,784
Other operating lease expenses 7,845 6,210 3,730 3,579
17,108 13,608 8,327 6,708
Thousands of Euros
At 30 June 2021, the Group has paid a total of Euros 41,000 thousand related to lease agreements (Euros 40,555
thousand at 30 June 2020).
The total amount recognized in the balance sheet corresponds to lease agreements in which the Group is the
lessee.
Rights of use depreciation
Six-Months
Ended 30 June
2021
Six-Months
Ended 30 June
2020
Three-Months
Ended 30 June
2021
Three-Months
Ended 30 June
2020
Not reviewed Not reviewed
Buildings 27,954 26,941 15,026 13,696
Machinery 940 823 502 420
Computer equipment 1,254 1,511 597 915
Vehicles 2,277 2,728 1,113 1,329
32,425 32,003 17,238 16,360
Thousands of Euros
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
17
(9) Equity-accounted investees
Movement in the investments in equity-accounted investees during the six-month period ended 30 June 2021 is
as follows:
Six-Months Ended
30 June 2021
Six-Months Ended
30 June 2020
Balance at 1 January 1,869,020 114,473
Acquisitions -- 1,804,619
Transfers (50,496) (10,674)
Share of profit / (losses) 49,093 (9,064)
Share of other comprehensive income / translation differences 39,110 (17,214)
Collected dividends (2,406) (1,790)
Balance at 30 June 1,904,321 1,880,350
Thousands of Euros
At 30 June 2021, the quoted value of SRAAS shares was CNY 7.49. In accordance with IAS 28 – Investments in
associates and joint ventures, possible indications of losses have been analyzed without detecting objective
evidence of impairment in the investment.
(10) Financial Assets
Details of non-current financial assets on the consolidated balance sheet at 30 June 2021 and 31 December 2020
are as follows:
Details of other current financial assets on the consolidated balance sheet at 30 June 2021 and 31 December 2020
are as follows:
30/06/2021 31/12/2020
Investments in quoted shares 1,947 3,008
Total Non-current financial assets measured at fair value 1,947 3,008
Non-current guarantee deposits 6,817 6,268
Other non-current financial assets 140,450 108,030
Non-current loans to related parties 83,429 80,851
Total Non-current financial assets at amortized cost 230,696 195,149
Thousands of Euros
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
18
(11) Trade and Other Receivables
At 30 June 2021 and during 2020, the Grifols Group has sold receivables without recourse to some financial
entities (factor), to which the risks and benefits inherent to the ownership of the assigned loans are substantially
transferred. Also, the control over the assigned credits, understood as the factor's ability to sell them to an
unrelated third party, unilaterally and without restrictions, has been transferred to the factor.
The main conditions of these contracts include the advanced collection of the transferred credits that varies
between 70% and 100% of the nominal amount and a percentage of insolvency risk coverage on the factor side
that varies between 90% and 100% of the nominal of the transferred credits.
These contracts have been considered without recourse factoring and the amount advanced by the factors has
been removed from the balance sheet.
Likewise, during 2021 and 2020, some credit rights assignment contracts were signed with a financial institution,
in which Grifols retains the risks and benefits inherent to the property of the assigned credits. These contracts
have been considered with resource and the transferred amount remains in the consolidated balance sheet and a
short-term debt has been recognized for an amount equal to the consideration received from the factor for the
transfer. The amount recognized is Euros 21,986 thousand at 30 June 2021 (Euros 18,264 thousand at 31
December 2020) (see note 13).
The total sum of credit receivables sold without recourse, for which ownership was transferred to financial
institutions pursuant to the aforementioned agreements, amounts to Euros 1,504,915 thousand for the six-month
period ended 30 June 2021 (Euros 1,282,858 thousand for the six-month period ended 30 June 2020 and Euros
2,735,973 thousand for the year ended 31 December 2020).
The finance cost of receivables sold amounts to Euros 5,320 thousand for the six-month period ended 30 June
2021, which has been recognized under finance costs in the consolidated statement of profit and loss (Euros
5,027 thousand for the six-month period ended 30 June 2020) (see note 15).
(12) Equity
Details of consolidated equity and changes are shown in the condensed consolidated statement of changes in
equity, which forms an integral part of the condensed consolidated interim financial statements.
(a) Share capital and share premium
At 30 June 2021 and 31 December 2020, the Company’s share capital amounts to Euros 119,603,705 and
comprises:
Class A shares: 426,129,798 ordinary shares of Euros 0.25 par value each, subscribed and fully paid and of
30/06/2021 31/12/2020
Deposits and guarantees 1,044 162
Other current financial assets 637 10,861
Current loans to third parties 8,000 95
Current financial assets at amortized cost 9,681 11,118
Thousands of Euros
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
19
the same class and series.
Class B shares: 261,425,110 non-voting preference shares of 0.05 Euros par value each, of the same class
and series, and with the preferential rights set forth in the Company’s by-laws.
(b) Reserves
The availability of the reserves for distribution is subject to legislation applicable to each of the Group
companies. At 30 June 2021, Euros 29,834 thousand equivalent to the carrying amount of development costs
pending amortization of certain Spanish companies (Euros 40,362 thousand at 31 December 2020) are, in
accordance with applicable legislation, restricted reserves which cannot be distributed until these
development costs have been amortized.
Companies in Spain are obliged to transfer 10% of each year’s profits to a legal reserve until this reserve
reaches an amount equal to 20% of share capital. This reserve is not distributable to shareholders and may
only be used to offset losses if no other reserves are available. Under certain conditions it may be used to
increase share capital provided that the balance left on the reserve is at least equal to 10% of the nominal
value of the total share capital after the increase.
At 30 June 2021 and 31 December 2020 the legal reserve of the Parent amounts to Euros 23,921 thousand.
(c) Treasury stock
Movement in Class A treasury stock during the six-month period ended 30 June 2021 is as follows:
On the meeting held on March 11, 2021, the Board of Directors resolved to implement a buy-back program
of Grifols’ own shares (the Buy-back Program), in accordance with the authorization granted by Grifols’
ordinary general shareholders’ meeting held on October 9, 2020, under item twelve of its agenda.
The Buy-back Program was created with the goal of using Grifols’ own shares (Class A and Class B) as a
consideration in certain future acquisitions that Grifols may carry out (as the Company has done in previous
occasions).
This Buy-back Program started on March 12, 2021, and has remained in force until June 14, 2021 (both days
included). Nevertheless, Grifols reserved the right to early terminate the Buy-back Program under certain
circumstances.
Grifols entrusted the execution of the Buy-back Program to an independent bank, so Grifols has not exercised
control over the bank’s decisions in this respect.
At 30 June 2020 the Company did not have Class A treasury stock.
Movement in Class B treasury stock during the six-month period ended 30 June 2021 is as follows:
No. of Class A shares Thousand of Euros
Balance at 1 January 2021 -- --
Disposals Class A shares -- --
Acquisition Class A shares 3,944,430 89,959
Balance at 30 June 2021 3,944,430 89,959
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
20
In March 2021 the Group delivered 361,530 treasury stocks (Class B shares) to eligible employees as
compensation for the Restricted Share Unit Retention Plan (see note 18 (b)).
Movement in Class B treasury stock during the six-month period ended 30 June 2020 is as follows:
In March 2020 the Company delivered 400,421 treasury stocks (Class B shares) to eligible employees as
compensation for the Restricted Share Unit Retention Plan (see note 18 (b)).
(d) Distribution of profits
The profits of Grifols, S.A. and subsidiaries will be distributed as agreed by the respective shareholders at
their general meetings and the proposed distribution of profit for the year ended 31 December 2020 is
presented in the consolidated statement of changes in equity.
Dividends paid during the six-month period ended 30 June 2021 were as follows:
In 2020, as a result of the situation derived from the COVID-19 pandemic, the Shareholders meeting was
delayed and it was hold during the last quarter of the year.
For this reason, no dividends were paid during the six-month period ended 30 June 2020.
No. of Class B shares Thousand of Euros
Balance at 1 January 2021 3,012,164 43,734
Disposals Class B shares (361,530) (5,248)
Acquisition Class B shares 2,419,896 35,744
Balance at 30 June 2021 5,070,530 74,230
No. of Class B shares Thousand of Euros
Balance at 1 January 2020 3,415,052 49,584
Disposals Class B shares (400,421) (5,814)
Balance at 30 June 2020 3,014,631 43,770
% of par value Euros
per share Thousands of Euros
Ordinary Shares 146% 0.36 154,005
Non-voting shares 729% 0.36 93,515
Non-voting shares (Preferred Dividend) 20% 0.01 2,614
Total Dividends Paid 250,134
Six-Months Ended 30 June 2021
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
21
(e) Restricted Share Unit Compensation
The Group has set up a Restricted Share Unit Retention Plan (hereinafter RSU) for certain employees (see
note 18 (b)). This commitment is settled using equity instruments and the cumulative accrual amounts to
Euros 8,471 thousand in June 2021 (Euros 13,880 thousand in December 2020).
(13) Financial Liabilities
Details of financial liabilities at 30 June 2021 and 31 December 2020 are as follows:
On 15 November 2019 the Group concluded the refinancing process of its senior secured debt for Euros
5,800 million. The new financing includes a Term Loan B for US Dollars 2,500 million and Euros 1,360
million, both aimed at institutional investors; the issue of two bonds for a total amount of Euros 1,675
million (Senior Secured Notes); and the extension of a multi-currency revolving credit facility up to US
Dollars 500 million.
On 7 May 2020, the Group concluded the upsize of the multi-currency revolving credit facility from US
Dollars 500 million to US Dollars 1,000 million with maturity in November 2025.
In September 2018, Grifols obtained a new non-current loan from the European Investment Bank totaling
Euros 85,000 thousand that will be used by Grifols to support its investments in R&D&i, mainly focused
on the search for new therapeutic indications for plasma-derived protein therapies. The financial terms
include a fixed interest rate and, a maturity of 10 years with a grace period of 2 years.
On 5 December 2017 and 28 October 2015, the Group arranged loans with the same entity and with the
same conditions for amounts of Euros 85,000 thousand and Euros 100,000 thousand, respectively. At 30
June 2021 and 31 December 2020, the carrying amount of the loans obtained from the European Investment
Bank amounts to Euros 212,500 thousand.
Financial liabilities 30/06/2021 31/12/2020
Non-current obligations (a) 2,675,000 2,675,000
Senior secured debt (b) 3,381,921 3,335,415
Other loans 183,244 183,771
Other non-current financial liabilities 9,374 10,272
Non-current lease liabilities (note 8) 737,830 690,857
Loan transaction costs (271,887) (293,215)
Total non-current financial liabilities 6,715,482 6,602,100
Current obligations (a) 130,700 125,843
Senior secured debt (b) 34,686 34,035
Other loans 745,190 170,730
Other current financial liabilities 41,389 105,041
Current lease liabilities (note 8) 45,315 42,642
Loan transaction costs (56,374) (53,679)
Total current financial liabilities 940,906 424,612
Thousands of Euros
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
22
(a) Senior Notes
On 15 November 2019, as part of its refinancing process, Grifols, S.A. issued Euros 1,675 million of Senior
Secured Notes segmented in two notes of Euros 770 million and Euros 905 million. These notes will mature
in 2027 and 2025 and will bear interest at an annual rate of 2.25% and 1.625%, respectively.
On 15 November 2019 the notes were admitted to listing on the Irish Stock Exchange.
On 18 April 2017, Grifols, S.A., issued Euros 1,000 million of Senior Unsecured Notes that will mature in
2025 and will bear interest at an annual rate of 3.20%. On 2 May 2017 the notes were admitted to listing
on the Irish Stock Exchange.
The total principal plus interest payable of the Senior Notes is detailed as follows:
(b) Senior Secured Debt
Current loans and borrowings include accrued interest amounting to Euros 9,793 thousand at 30 June 2021
(Euros 7,262 thousand at 31 December 2020).
On 15 November 2019 the Group refinanced its Senior Secured Debt with the existing lenders. The new
senior debt consists of a Term Loan B (“TLB”), which amounts US Dollars 2,500 million and Euros 1,360
million with a 2.00% margin pegged to Libor and a 2.25% margin pegged to Euribor respectively, maturity
in 2027 and quasi-bullet repayment structure. The borrowers of the total senior debt are Grifols, S.A. and
Grifols Worldwide Operations USA, Inc.
The costs of refinancing the senior debt amounted to Euros 84.4 million.
The terms and conditions of the senior secured debt are as follows:
o Tranche B: eight-year loan divided into two tranches: US Tranche B and Tranche B in Euros.
Tranche B in US Dollars:
Original principal amount of US Dollars 2,500 million.
Applicable margin of 200 basis points (bp) linked to US Libor.
Quasi-bullet repayment structure.
Maturity in 2027
Tranche B in Euros:
Original principal amount of Euros 1,360 million.
Applicable margin of 225 basis points (bp) linked to Euribor.
Senior Unsecured Notes Senior Secured Notes
Principal+Interest in
Thousands of Euros
Principal+Interest in
Thousands of Euros
Maturity
2021 16,000 16,016
2022 32,000 32,031
2023 32,000 32,031
2024 32,000 32,031
2025 1,016,000 929,678
2026 -- 17,325
2027 -- 787,325
Total 1,128,000 1,846,437
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
23
Quasi-bullet repayment structure.
Maturity in 2027
Details of the Tranche B by maturity at 30 June 2021 are as follows:
The total principal plus interest of Tranche B Senior Loan is as follows:
o US Dollar 1,000 million committed credit revolving facility: On 7 May 2020, the Group concluded the
upsize of the multi-currency revolving credit facility from US Dollars 500 million to US Dollars 1,000
million with maturity in November 2025 and an applicable margin of 150 basis points (bp) linked to US
Libor.
The costs of refinancing the revolving credit facility amounted to Euros 9.3 million.
At 30 June 2021 the Group has drawn down a total amount of US Dollars 350 million and Euros 240 million
on this facility.
Both the Senior Term Loans and the Revolving Loans are secured by Grifols, S.A. and certain significant
subsidiaries of Grifols, S.A., which together with Grifols, S.A., represent, in the aggregate, at least 70% of
consolidated EBITDA of the Group.
Currency Principal in thousands of
US Dollars
Principal in thousands
of Euros Currency Principal in
thousands of Euros
Maturity
2021 US Dollars 12,500 10,543 Euros 6,800
2022 US Dollars 25,000 21,086 Euros 13,600
2023 US Dollars 25,000 21,086 Euros 13,600
2024 US Dollars 25,000 21,086 Euros 13,600
2025 US Dollars 25,000 21,086 Euros 13,600
2026 US Dollars 25,000 21,086 Euros 13,600
2027 US Dollars 2,325,000 1,961,033 Euros 1,264,801
Total US Dollars 2,462,500 2,077,006 Euros 1,339,601
Tranche B in US Dollars Tranche B in Euros
Thousand of Euros
Tranche B Senior Loan
Maturity
2021 54,845
2022 108,510
2023 107,754
2024 107,197
2025 106,242
2026 105,485
2027 3,287,085
Total 3,877,118
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
24
The Notes have been issued by Grifols S.A. and are guaranteed on a senior secured basis by subsidiaries of
Grifols, S.A. that are guarantors and co-borrower under the New Credit Facilities. The guarantors are Grifols
Worldwide Operations Limited, Biomat USA, Inc., Grifols Biologicals Inc., Grifols Shared Services North
America, Inc., Talecris Plasma Resources, Inc.., Grifols Therapeutics, Inc., Instituto Grifols, S.A., Grifols
Worldwide Operations USA, Inc., Grifols USA, Llc. and Grifols International, S.A.
(14) Expenses by Nature
Details of wages and other employee benefits expenses by function are as follows:
Details of amortization and depreciation expenses by function are as follows:
Six-Months
Ended 30 June
2021
Six-Months
Ended 30 June
2020
Three-Months
Ended 30 June
2021
Three-Months
Ended 30 June
2020
Not reviewed Not reviewed
Cost of sales 101,389 100,048 51,859 50,927
Research and development 19,338 13,337 9,647 7,255
Selling, general & administrative expenses 46,027 44,831 23,473 22,461
166,754 158,216 84,979 80,643
Thousands of Euros
Six-Months
Ended 30 June
2021
Six-Months
Ended 30 June
2020
Three-Months
Ended 30 June
2021
Three-Months
Ended 30 June
2020
Not reviewed Not reviewed
Cost of sales 488,224 563,519 242,581 288,298
Research and development 66,156 56,399 36,003 27,891
Selling, general & administrative
expenses 183,865 205,139 84,649 102,319
738,245 825,057 363,233 418,508
Thousands of Euros
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
25
(15) Finance Result
Details are as follows:
Six-Months
Ended 30 June
2021
Six-Months Ended
30 June 2020
Three-Months
Ended 30 June
2021
Three-Months
Ended 30 June
2020
Not reviewed Not reviewed
Finance income 4,949 4,580 1,804 1,982
Finance cost from Senior
Unsecured Notes (41,916) (42,667) (21,009) (21,233)
Finance cost from Senior debt (54,035) (63,065) (27,178) (29,260)
Finance cost from sale of
receivables (note 11) (5,320) (5,027) (2,742) (3,005)
Capitalised interest 8,609 9,102 4,485 4,349
Finance lease expense (note 8) (17,133) (18,055) (8,701) (9,117)
Other finance costs (9,903) (6,568) (5,916) (3,460)
Finance costs (119,698) (126,280) (61,061) (61,726)
Change in fair value of financial
instruments (note 3) 555 56,526 -- --
Exchange differences (5,243) (10,755) (1,480) 661
Finance result (119,437) (75,929) (60,737) (59,083)
Thousands of Euros
(16) Taxation
Income tax expense is recognized based on management’s best estimate of the weighted average annual income
tax rate expected for the full financial year applied to the pre-tax income of the interim period. The Group’s
consolidated effective tax rate is 20% for the six-month period ended 30 June 2021 and for the six-month period
ended 30 June 2020.
No relevant events have arisen regarding income tax audits during the six-month period ended 30 June 2021.
(17) Discontinued operations
The Group has not discontinued any operations for the six-month periods ended 30 June 2021 and 2020.
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
26
(18) Contingencies and Commitments
(a) Contingencies
Details of legal proceedings in which the Company or Group companies are involved are as follows:
ORTHO-CLINICAL DIAGNOSTICS, INC., GRIFOLS DIAGNOSTIC SOLUTIONS, INC. adv.
SIEMENS HEALTHCARE DIAGNOSTICS, INC.
Served: 20 November 2018
Contract Dispute
Ortho-Clinical Diagnostics, Inc. ("Ortho") and Grifols Diagnostic Solutions, Inc. ("GDS") initiated a dispute
with Siemens Healthcare Diagnostics, Inc. ("Siemens") regarding sales and commissions under the Supply and
Agency Agreement alleging underpayments.
NEXT ACTION: Trial concluded March 18, 2021. Awaiting decision by the Tribunal.
Siemens has now initiated separate but related dispute resolution with Ortho and GDS under the Supply
Agreement, specific to pricing, alleging overpayments.
NEXT ACTION: GDS and Ortho filed a motion to stay the arbitration in New York Supreme Court,
Commercial Division, pending the outcome of the dispute regarding the Supply and Sales Agency Agreements,
which motion is still pending before that Court. A Tribunal was appointed and scheduling order is in place.
Discovery has been initiated.
ABBOTT LABORATORIES v. GRIFOLS DIAGNOSTIC SOLUTIONS INC., GRIFOLS
WORLDWIDE OPERATIONS LIMITED AND NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Served: 8 October 2019
US District Court, Northern District of Illinois
Patent Infringement, Civil Action No. 1:19-cv-6587
Abbott Laboratories (“Abbott”), GDS, GWWO and Novartis Vaccines and Diagnostics, Inc. are in dispute over
unpaid royalties payable by Abbott to GDS and Ortho-Clinical Diagnostics (“Ortho”) under an HIV License
and Option agreement dated 16 August 2019 (the “HIV License”). On 12 September 2019, GDS and Ortho
filed Notice of Arbitration. On 3 October 2019, Abbott terminated the HIV License and filed for Declaratory
Relief seeking to invalidate the licensed patent. GDS filed Motions to Dismiss and to Compel Arbitration, but
the Court continued all pending Motions and referred the parties to a magistrate for a mandatory settlement
conference. On 5th February the parties attended a Mandatory Settlement Conference ordered by the District
Judge, with the Magistrate Judge presiding. No satisfactory settlement was reached. On March 16, 2020,
Grifols and Ortho filed an answer and counterclaim to the litigation, while simultaneously pursuing arbitration
for the pre-termination amount owed by Abbot. The arbitration hearing was June 15-16, 2020. As a result,
the arbitrator awarded Grifols/Ortho $4 Million. The court litigation is continuing. Abbot’s Motion to Dismiss
was denied December 1, 2020. Discovery is now still underway.
(b) Commitments
Restricted Share Unit Retention Plan
For the annual bonus, the Group established a Restricted Share Unit Retention Plan (RSU Plan), for eligible
employees. By these plans, the employee could elect to receive up to 50% of its yearly bonus in non-voting Class
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
27
B ordinary shares (Grifols Class B Shares) or Grifols American Depositary Shares (Grifols ADS), and the Group
will match with an additional 50% of the employee election of RSUs (additional RSUs).
Grifols Class B Shares and Grifols ADS are valued at grant date.
These RSUs will have a vesting period of 2 years and 1 day and, subsequently, the RSU's will be exchanged for
Grifols Class B Shares or Grifols ADS (American Depositary Share representing 1 Class B Share).
If an eligible employee leaves the Company or is terminated before the vesting period, he will not be entitled to
the additional RSU.
At 30 June 2021, the Group has settled the RSU plan of 2018 for an amount of Euros 8,221 thousand (Euros 7,509
thousand at 30 June 2020 regarding RSU plan of 2017).
This commitment is treated as equity-settled and the accumulated amount recognized as at 30 June 2021 as share
based payments costs of employees is Euros 8,471 thousand (Euros 13,880 thousand at December 2020).
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)
28
(19) Financial Instruments
Classification
Disclosure of financial instruments by nature, category and fair value is as follows:
The Group does not provide details of the fair value of certain financial instruments as their carrying amount is very similar to their fair value because of its short term.
Financial assets
at amortised
costs
Financial assets at
FV to profit or
loss
Financial
assets at FV
to OCI
Financial
liabilities at
amortised costs
Other
financial
liabilities
Total Level 1 Level 2 Level 3 Total
Non-current financial assets -- 1,128 1,880 -- -- 3,008 1,128 -- 1,880 3,008
Trade receivables -- -- 308,485 -- -- 308,485 -- 308,485 -- 308,485
Financial assets measured at fair value -- 1,128 310,365 -- -- 311,493
Non-current financial assets 195,149 -- -- -- -- 195,149 --
Other current financial assets 11,118 -- -- -- -- 11,118
Trade and other receivables 147,108 -- -- -- -- 147,108
Cash and cash equivalents 579,647 -- -- -- -- 579,647
Financial assets not measured at fair value 933,022 -- -- -- -- 933,022
--
Senior Unsecured & Secured Notes -- -- -- (2,601,479) -- (2,601,479) (2,705,437) -- -- (2,705,437)
Promissory Notes -- -- -- (111,622) -- (111,622)
Senior secured debt -- -- -- (3,110,298) -- (3,110,298) -- (3,358,729) -- (3,358,729)
Other bank loans -- -- -- (354,501) -- (354,501)
Lease liabilities -- -- -- (733,499) -- (733,499)
Other financial liabilities -- -- -- (115,313) -- (115,313)
Other non-current debts -- -- -- -- (16,391) (16,391)
Trade and other payables -- -- -- (742,707) -- (742,707)
Other current liabilities -- -- -- -- (153,162) (153,162)
Financial liabilities not measured at fair value -- -- -- (7,769,419) (169,553) (7,938,972)
933,022 1,128 310,365 (7,769,419) (169,553) (6,694,457)
Thousands of Euros
31/12/2020
Carrying amount Fair Value
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)
29
The Group does not provide details of the fair value of certain financial instruments as their carrying amount is very similar to their fair value because of its short term.
Financial assets
at amortised
costs
Financial assets
at FV to profit or
loss
Financial
assets at FV
to OCI
Financial
liabilities at
amortised costs
Other
financial
liabilities
Total Level 1 Level 2 Level 3 Total
Non-current financial assets -- 7 1,940 -- -- 1,947 7 -- 1,940 1,947
Trade receivables -- -- 457,180 -- -- 457,180 -- 457,180 -- 457,180
Financial assets measured at fair value -- 7 459,120 -- -- 459,127
Non-current financial assets 230,696 -- -- -- -- 230,696
Other current financial assets 9,681 -- -- -- -- 9,681
Trade and other receivables 154,384 -- -- -- -- 154,384
Cash and cash equivalents 397,864 -- -- -- -- 397,864
Financial assets not measured at fair value 792,625 -- -- -- -- 792,625
--
Senior Unsecured & Secured Notes -- -- -- (2,609,818) -- (2,609,818) (2,709,042) -- -- (2,709,042)
Promissory Notes -- -- -- (115,172) -- (115,172)
Senior secured debt -- -- -- (3,169,056) -- (3,169,056) -- (3,391,499) -- (3,391,499)
Other bank loans -- -- -- (928,434) -- (928,434)
Lease liabilities -- -- -- (783,145) -- (783,145)
Other financial liabilities -- -- -- (50,763) -- (50,763)
Other non-current debts -- -- -- -- (16,767) (16,767)
Trade and other payables -- -- -- (757,568) -- (757,568)
Other current liabilities -- -- -- -- (181,629) (181,629)
Financial liabilities not measured at fair value -- -- -- (8,413,956) (198,396) (8,612,352)
792,625 7 459,120 (8,413,956) (198,396) (7,360,600)
Thousands of Euros
30/06/2021
Carrying amount Fair Value
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
30
(20) Related Parties
Transactions with related parties have been performed as part of the Group’s ordinary course of business and have
been performed at arm’s length.
Group transactions with related parties during the six-month period ended 30 June 2021 are as follows:
Associates Key management
personnel
Other related
parties
Board of directors
of the company
Net Sales 145,685 -- -- --
Purchases of inventory (358) -- -- --
Other service expenses (175) -- (3,890) --
Remuneration -- (7,722) -- (2,232)
Dividends paid/received (6,405) -- -- --
138,747 (7,722) (3,890) (2,232)
Thousands of Euros
Group transactions with related parties during the six-month period ended 30 June 2020 were as follows:
Group transactions with related parties during the three-months period ended 30 June 2021 were as follows:
Associates Key management
personnel
Other related
parties
Board of directors
of the company
Net sales 5,456 -- -- --
Purchases of inventory (30) -- -- --
Other service expenses (14,687) -- (7,363) --
Purchases of fixed assets -- (13,500)
Remuneration -- (8,486) -- (2,500)
Finance income 783 -- -- --
(8,479) (8,486) (20,863) (2,500)
Thousands of Euros
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Notes to Condensed Consolidated Interim Financial Statements for the six-
month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version
prevails)
31
Associates Key management
personnel
Other related
parties
Board of directors
of the company
Net Sales 142,765 -- -- --
Purchases of inventory (240) -- -- --
Other service expenses (123) -- (1,511) --
Remuneration -- (3,844) -- (1,117)
Dividends paid/received (6,405) -- -- --
135,997 (3,844) (1,511) (1,117)
Thousands of Euros
Not reviewed
Group transactions with related parties during the three-months period ended 30 June 2020 were as follows:
On 28 December 2018, the Group sold BPC Plasma and Haema to Scranton Enterprises B.V (shareholder of
Grifols) for US Dollars 538,014 thousand. For the payment of the aforementioned sale amount, Scranton signed
a loan agreement dated 28 December 2018 for an amount of US Dollars 95,000 thousand (Euros 82,969 thousand)
with Grifols Worldwide Operations Limited. Interest on this loan is 2%+EURIBOR and it falls due on 28
December 2025.
The Group has not extended any advances or loans to the members of the board of directors or key management
personnel nor has it assumed any guarantee commitments on their behalf. It has also not assumed any pension or
life insurance obligations on behalf of former or current members of the board of directors or key management
personnel. In addition, as disclosed in note 29(c) of the consolidated financial statements as at and for the year
ended 31 December 2020, certain Company directors and key management personnel are entitled to termination
benefits.
Associates Key management
personnel
Other related
parties
Board of directors
of the company
Net sales 2,231 -- -- --
Purchases of inventory (25) -- -- --
Other service expenses (6,542) -- (5,172) --
Purchases of fixed assets -- -- (13,500) --
Remuneration -- (4,189) -- (1,250)
Finance income 461 -- -- --
(3,875) (4,189) (18,672) (1,250)
Thousands of Euros
Not reviewed
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
1
You are encouraged to read the following discussion and analysis of Grifols’ financial condition and results of
operations together with their six months period ended June 30, 2021 condensed consolidated interim financial
statements and related footnotes. This discussion and analysis may contain forward-looking statements that
involve risks and uncertainties. See the section “Cautionary Statement Regarding Forward-Looking
Statements” included in this document.
Grifols reported 2.3% cc1 (-5.3% taking into account exchange rate variations) growth and EUR 2,536.6
million in revenues in the first half, a period marked by the gradual recovery of plasma donations, debt
reduction, and significant investment efforts to further consolidate plasma supply levels and innovation.
In the second quarter of 2021, revenues grew by 5.3% cc to EUR 1,351.9 million, fueled by the solid
performance of the Bioscience, Diagnostic and Hospital divisions.
The Bioscience Division recorded notable 5.1% cc growth, reversing the 5.6% cc decline recorded in the
first quarter. First-half revenues totaled EUR 1,986.0 million (-0.1% cc; -8.0%).
The division’s growth was driven by robust demand for all major plasma proteins – immunoglobulins
(IVIG and SCIG), albumin, alpha-1 and specialty proteins – coupled with mid-single-digit price increases and
the contribution of new products.
The Diagnostic Division delivered EUR 395.5 million in sales in the first six months of 2021, growing by
22.9% cc (16.3%), mainly due to sales of the TMA (Transcription-Mediated Amplification) molecular test to
detect the SARS-CoV-2 virus, as well as underlying growth of NAT technology (Procleix® NAT Solutions)
solutions, used to screen whole blood and plasma.
Hospital Division revenues increased for the third consecutive quarter as hospital investments and
treatments normalize. The division registered revenues of EUR 67.7 million in the first half, an operational
increase of 19.5% cc (17.1%).
Bio Supplies Division’s sales totaled EUR 107.3 million, a 8.5% cc decline (-15.4%) mainly as a result of
lower third-party plasma sales and Bio Supplies Commercial phasing.
The gross margin in the first half was 43.9%, compared to 38.8% reported in the same period last year.
The gross margin for the second quarter stood at 43.0%.
EBITDA reached EUR 634.5 million (EUR 337.7 million in the second quarter), a 9.4% increase during
the first half. The EBITDA margin is 25.0% over revenues (25.1% in the first quarter).
Grifols continues to execute its EUR 100 million per year operating expense containment plan, enabling
the company to optimize its financial performance without impacting on its innovation efforts.
Throughout the first six months of 2021, Grifols has continued working on expanding its long-term plasma
supply to meet current market needs and the anticipated robust demand.
Today, plasma collections in Europe exceed 2020 levels and pre-pandemic levels. U.S. plasma collections
continue its upward trend. Recent strategic acquisitions increased Grifols' plasma collection capacity, providing
access to an additional 1.4 million liters per year. Currently, the capacity is 16.5 million liters per year. In
parallel, the company plans on opening 15 to 20 new centers in the second half of 2021.
The company reaffirmed its firm commitment to innovation, combining its extensive experience in
plasma-derived medicines while progressively developing a complementary portfolio of non-plasma therapies.
1 Constant currency (cc) excludes exchange rate fluctuations over the period.
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
2
In this context, total net investment in R+D+i amounted to EUR 155.3 million, representing 6.1% of revenues.
These results underscore Grifols’ ongoing efforts to integrate and develop cutting-edge projects as those of
Alkahest and GigaGen.
Grifols allocated EUR 117.3 million (EUR 145.6 million in the first half of 2020) to CAPEX.
The financial result in the first half of 2021 stood at EUR 119.4 million (EUR 132.4 million in the first
half of 2020 excluding the positive EUR 56.5 million impact from the closing of the Shanghai RAAS transaction
registered in that period).
Share of results of equity-accounted investees mainly includes the updated value of Grifols’ GigaGen
stake (EUR 34.5 million), following the agreement signed in the first quarter of 2021 to acquire the remaining
capital.
The reported net profit totaled EUR 266.8 million, a 22.3% increase over the EUR 218.2 million recorded
in the same period of 2020. This figure includes part of the COVID-192 impact. The adjusted net profit amounts
to EUR 279.1 million.
Excluding the impact of IFRS 163, the net financial debt reached EUR 6,475.5 million. In recent quarters,
the leverage ratio has increased due to strategic acquisitions totaling USD 1 billion to secure plasma supply,
reinforce innovation and support global expansion.
Decreasing leverage remains a priority for the company. In the first half of 2021, Grifols reduced the net
financial debt over EBITDA ratio to 4.9x, down from the 5.1x reported until the first quarter of the year.
The GIC, the sovereign wealth fund of Singapore, agreement will also further reduce leverage by 0.6x,
since the capital will be allocated in full to repay senior debt. GIC will become a long-term strategic investor
for the next 30 years as a result of this transaction.
As of June 30, 2021, Grifols’ cash position totaled EUR 398 million, bringing its liquidity position to EUR
813 million.
The efforts to increase plasma capacity, business optimization, global expansion, innovation and financial
discipline leave Grifols well positioned to respond to current needs and fulfill its commitments and growth
strategy.
PERFORMANCE BY DIVISION
Bioscience Division
The Bioscience Division recorded EUR 1,986.0 million in revenues (-0.1% cc and -8.0%). The growth of
5.1% cc (-3.1%) in sales in the second quarter to EUR 1,084.7 million has offset the decrease of 5.6% cc
(-13.3%) recorded in the first quarter.
Strong demand was noted for the main proteins including IG, albumin, alpha-1 and specialty proteins
(hyperimmune and intramuscular immunoglobulins), was backed by mid-single-digit price increases. This trend
partially offset lower sales volume of IVIG.
New product launches including Xembify®, VISTASEALTM and TAVLESSE® also contributed to the
revenue performance.
2 In the first half of 2020, Grifols recognized an estimated impact of EUR 205 million for the entire 2020 financial year to
adjust inventory value as a result of COVID-19.
3 As of June 30, 2021, the impact of IFRS 16 on total debts stands at EUR 783 million.
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
3
Immunoglobulin demand remains very strong, led by the U.S., Canada and several European Union (EU)
countries. The contribution of subcutaneous immunoglobulins (SCIG) were particularly noteworthy in the
second quarter.
Albumin sales maintain their trend driven by double-digit growth in China, whose demand continues to
present a significant growth potential. Albumin sales also grew in traditional markets such as the U.S., Europe
and Latin America, where demand remains robust.
In July 2021, Grifols introduced Plasbumin® in China, the company's third brand launch in this market. As
part of Grifols’ strategic alliance with Shanghai RAAS, Plasbumin® will be marketed via a new integrated
commercial platform. Encompassing more than 500 business partners and access to direct sales, this network
boasts a large geographic scope, extensive market coverage and expanded customer base.
Alpha-1 antitrypsin continues to drive the division’s revenues, attaining double-digit growth in the second
quarter. The company remains committed to increasing the diagnosis of alpha-1-antitrypsin deficiency patients,
particularly in countries such as Germany and France.
The performance of specialty proteins, including hyperimmune and intramuscular immunoglobulins, was
very positive and grew by double digit in the first six months. Of note were strong U.S. sales of Grifols’ anti-
rabies immunoglobulin (HyperRAB®) and the U.S. market launch of a new format of anti-hepatitis B
immunoglobulin (HyperHEP B®), currently prescribed in more than 20 countries.
In terms of new products, TAVLESSE® (fostamatinib) recorded strong sales in European countries where
it has been launched. Within the framework of the agreement with Rigel Pharmaceuticals, it is used to treat
chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments.
Diagnostic Division
Diagnostic Division revenues grew by 22.9% cc (+16.3%) in the first half of the year to EUR 395.5 million,
driven by its main business lines. Sales in the second quarter were especially strong, reaching EUR 192.2
million and double-digit growth.
Revenues of Grifols’ NAT systems (Procleix® NAT Solutions), used to screen whole blood and plasma
donations via Transcription-Mediated Amplification (TMA) continues to show its dynamism. Of note are strong
sales of the TMA diagnostic test used to detect SARS-CoV-2, which, in addition to its high sensitivity, can also
adapt to large volumes of samples in an automated way.
The blood typing line has also resumed its previous trend with significant growth in the U.S., various
European countries and Japan. Its sales include both analyzers (Erytra®, Erytra-Eflexis® and Wadiana®) and
reagents (DG-Gel® cards, red blood cells and antiserums). Of note is the first Eflexis installation in Austria.
Additionally, sales of recombinant proteins to produce diagnostic immunoassays remain stable. The design
and development of a new recombinant protein (sCD38) is worth highlighting. This product will enhance the
safety of blood transfusions in cancer patients, a significant advance in the area of immune-hematological
testing.
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
4
Hospital Division
The Hospital Division reported EUR 67.7 million in revenues, growing by 19.5% cc (+17.1%) as hospital
investments recover. A positive performance is observed in all business lines, particularly Pharmatech,
intravenous solutions and third-party manufacturing services.
In the field of oncology, the division announced the installation of two new Kiro Oncology systems in the
U.S., one in New York’s Mount Sinai-The Blavatnik Family Chelsea Medical Center and the other in the Seattle
Cancer Center Alliance, the only cancer center in the state of Washington.
Bio Supplies Division
Bio Supplies Division revenues reached EUR 107.3 million in the first six months, a 8.5% cc decrease
(-15.4%) compared to the same period in the previous year due mainly to lower whole blood collections and
Bio Supplies Commercial sales phasing.
STRATEGIC AGREEMENTS AND INNOVATION
Strategic investment from GIC in Biomat
In line with Grifols’ commitment to reduce its leverage levels, the company takes a step further and
welcomes GIC as a strategic investor. Grifols’ leadership in the manufacture of plasma-based medicines,
extensive expertise in the expansion and management of plasma centers, market know-how, and outstanding
reputation were all key factors in GIC’s decision to invest in the company.
As previously announced, Grifols S.A. has signed a corporate transaction by means of which an affiliate
of GIC, the sovereign wealth fund of Singapore, have entered into a definitive agreement under which GIC
will invest US$990 million in Grifols’ wholly-owned US subsidiary Biomat USA, Inc. (“Biomat”). In
exchange, GIC will receive an aggregate of 10 Class B common shares of Biomat and 9 Class B common
shares of a newly-established sub-holding company (“Newco”). These common shares, which will represent
directly and indirectly an aggregate of 23.8% of the equity of Biomat, will be non-voting but will have annual
preferential dividends of US$4,168,421.05 per share of each of Biomat and Newco. Beginning with respect to
2023, holders of these shares may request, subject to certain limitations, the redemption of up to one share of
Biomat or Newco per year, as applicable, at a redemption price of $52,105,263.16 per share (the “redemption
price”), provided that following the 15th anniversary of the closing of the transaction,, holders may request
redemption of up to all their then outstanding shares. The shares will have customary liquidation preference
rights (in an amount per share equal to the redemption price plus unpaid dividends) that would trigger in certain
circumstances, such as in the case of a liquidation, dissolution or winding up of Biomat, if Grifols ceases to
control or have at least a 75% voting interest in Biomat, or upon the exclusive licensing of all or substantially
all intellectual property of Biomat. In addition, in the event of a default in the payment of dividends or
redemptions, there would among other things be monetary penalties or holders of the shares could opt to
exchange them for shares of Grifols S.A.
Biomat (together with its subsidiaries) holds a plasma collection business with 296 plasma collection
centers throughout the territory of the United States. Grifols will continue to control all aspects of the day-to-
day management of Biomat and, through a long-term plasma supply agreement, all plasma collected by Biomat
and its subsidiaries will continue to be supplied to Grifols for the further manufacturing of plasma derived
products. Grifols intends to apply all net proceeds from GIC’s investment to repay debt.
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
5
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
6
Grifols reaffirms its commitment to innovation
As outlined during the annual investors and analysts meeting in June, Grifols remains committed to driving
innovation and advancing a strategic plan aimed at gradually developing a portfolio of non-plasma products to
complement its plasma-derived therapies.
To this end, the company is focused on technological platforms such as Alkahest’s and GigaGen’s to
accelerate research on a range of fields including dementia and other age-related conditions; cirrhosis and other
liver diseases; infectious diseases; and ophthalmology, one of the most innovative areas with significant growth
potential.
The company expects new product launches to account for 20% of revenues by 2030, compared to 5% at
present.
Collaborations to drive innovation and knowledge
The company signed an agreement with the Government of Andorra in April through the Andorra
Desenvolupament i Inversió (ADI) to create a world-class R+D+i center dedicated to developing treatments for
immune system disorders that can lead to autoimmune diseases, cancer, emerging infectious diseases and other
pathologies.
The parties will establish a joint venture owned by Grifols and ADI on an 80%-20% basis, respectively.
The agreement will become effective when the corresponding authorizations are available.
Another highlight in the second quarter was the inauguration of the first AMBAR® Center in Barcelona,
the fruit of Grifols’ collaboration with the Ace Alzheimer Center Barcelona Medical Foundation.
The center will collect real-world data from regular medical practice to optimize the application of
AMBAR® procedure so that it can become a viable option for Alzheimer's patients.
The center is the result of more than 15 years of research on Alzheimer's disease through the AMBAR®
clinical program, including an international clinical trial which has been demonstrated as a safety treatment to
slow down the cognitive and functional progression of Alzheimer’s disease in patients in the mild to moderate
stages of the disease.
Grifols has plans to open more AMBAR® Centers in Europe, the United States and China through
partnerships with medical institutions renowned for their work on this progressive neurologic disorder.
NON-FINANCIAL INFORMATION: COMMITMENT TO OUR TALENT POOL, THE ENVIRONMENT
AND SUSTAINABILITY
Grifols promotes the health, safety and continuous development of its employees
Assuring the health and safety of its team is among Grifols’ top priorities. In the first half of 2021, the
company executed all prevention measures recommended by health authorities as well as additional safety
measures to protect its employees against COVID-19. It also rolled out a sampling strategy to monitor staff
through biweekly diagnostic tests, administering more than 100,000 tests over the first six months of the year.
Additional efforts to safeguard the Grifols workforce include ISO 45001 certification, the world’s
international standard for occupational health and safety. The company’s installations in Spain are ISO-45001-
certified, with progress underway to obtain certification in the U.S.
Grifols’ workforce included 23,431 employees in the first half of the year, a 0.9% decrease compared to
the end of the 2020 financial year. Of note was the increase in ROW (rest of the world), where the workforce
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
7
increased by +2.1% to 2,661 employees. It contracted 1.6% to 16,490 employees in North America and
remained stable in Spain (-0.3%) with 4,280 employees.
The average seniority at Grifols is 6.3 years and the average age is 38 years old. The company advocates
equal opportunities for men and women. As of June 30, 2021, men comprise 40% of the employee pool, and
women, 60%.
Launched years ago, the company’s digital transformation process ensured the continuation of its various
training and talent development initiatives throughout the pandemic. Over the first six months of 2021, more
than 1,000 employees took part in over 100 workshops. Grifols managers also elevated their digital-
transformation competencies in an innovative program designed to foster the unique mindset, skills and
resources to excel in today’s digitally-driven landscape. Grifols employees dedicated an average of 53 hours to
training in the first half of 2021.
In the areas of diversity and inclusion, Grifols started a three-year strategic plan to promote gender equality,
the inclusion of disabled employees, minority representation, and an age-diverse workplace.
Environmental management
Grifols published its 2020 environmental performance and the advance of the 2020-2022 Corporate
Environmental Program in the first half of the year. Both documents are included in 2020 Integrated Annual
Report, which also outlines Grifols' progress on its 2030 environmental targets.
In 2020, the company made notable progress toward its 2030 objectives, with respect to the base year 2018,
achieving an 8.1% drop in CO2 equivalent emissions; a 9.4% decrease in energy consumption; 5.4%
consumption from renewable electricity; and a 68% decline in business-travel emissions and 30% drop from
employee commutes. Grifols supports various biodiversity protection programs, including projects in Clayton,
North Carolina (U.S.) and the Besòs River basin in Barcelona, Spain, in cooperation with the Rivus Foundation.
Among the initiatives implemented in 2021 under the 2020-2022 Corporate Environmental Program, worth
mention is the start-up of the third photovoltaic facility for self-consumption installed in Spain. It is a 220-kW
photovoltaic plant, installed on the roof of a Bioscience Division facility in Parets del Vallès (Barcelona, Spain)
and will generate 330,000 kWh per year.
Also noteworthy is the recent agreement PPA (Power Purchasing Agreement) signed with RWE
Renewables, for a period of 10 year, for the purchase of renewable electricity where Grifols will buy 28% of
its total annual electricity needs in Spain. Through the agreement, Grifols will be the sole customer of a new
21-hectare solar photovoltaic plant currently in construction in Las Vaguadas (Badajoz, Spain). The installation
is expected to be operative in the first half of 2022, providing 25 million kWh per year while preventing the
emission of more than 7,600 tons of CO2e per year.
Grifols foresees future PPAs in Spain and in other markets in which it operates, including the United States,
in order to modify its energy consumption and achieve its 2030 sustainability goals. These include obtaining at
least 70% of its electricity from renewable sources, cutting greenhouse gas emissions per unit of production by
40% and increasing energy efficiency per unit of production by 15%.
Meanwhile, the Bioscience Division facility in Ireland has implemented a process to reuse and recover
water from pasteurization baths, an initiative that will reduce its water consumption by 4,000 m3 per year.
Finally, Grifols’ waste-management initiatives in the Parets del Vallès complex (Barcelona) will increase
materials recycling from the general trash fraction and convert the last portion into solid recovered fuel,
avoiding more than 400 tons of non-hazardous waste per year go to the landfill.
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
8
Sustainability
- Working toward ESG commitments
Grifols reinforced its commitment to a long-term sustainable development model with the creation of the
Sustainability Steering Committee. This committee is led by the Investor Relations and Sustainability and
reports to the Sustainability Committee, delegated by the Board of Directors. Among its responsibilities, the
Sustainability Steering Committee will ensure making progress as a responsible, transparent company
committed to its various stakeholders through the continuous improvement of its economic, social,
environmental and corporate governance (ESG) performance.
In the first half, Grifols also formally ratified its commitment to a responsible business model that takes
into account the principles and objectives of the 2030 Agenda for Sustainable Development. In this sense, in
addition to integrating the Sustainable Development Goals (SDGs) into its corporate strategy and analyzing,
evaluating and communicating its commitments and contributions in detail each year; the company offered
further evidence of its commitment by formally joining the United National Global Compact, the world’s largest
initiative for corporate sustainability.
Grifols’ notable ESG performance in recent years has led to its distinction among the world’s most
sustainable companies. To date, it has been listed on premier sustainability indices including the Dow Jones
Sustainability Index (DJSI) Euro, Euronext Vigeo Europe 120, Euronext Vigeo Eurozone 120, FTSE4Good
Global and the Bloomberg Gender-Equality Index (GEI), among others.
At the same time, several ratings agencies such as Standard & Poor's (S&P) Global Rating, Moody's,
Sustainalytics and ISS evaluated Grifols' sustainability performance for the first time in 2021. Especially
noteworthy was the S&P and Sustainalytics ratings and ISS ESG Corporate classified the company in the
“prime” category.
- Transparency
As part of its commitment to transparency, Grifols disclosed, for the sixth consecutive year, all payments
and other transfers of value related to medicines and medical technology made to healthcare professionals and
health organizations in several European countries as defined by EFPIA, including Spain.
In 2020, Grifols’ transfers of value in Europe totaled EUR 13.4 million, a 14% decline in relation to the
previous year due to pandemic-related restrictions and limitations, which included the cancellation of several
research conferences or their conversion from in-person to online events. R+D-related value transfers amounted
to EUR 11.34 million and represented 84.4% of the total, reaching similar levels as those reported in 2019.
In addition to Europe, Grifols applies this policy of transparency in the United States as required by the
regulatory body (Centers for Medicare & Medicaid Services, CMS).
- Social Action
Grifols has extended its commitment to the World Federation of Hemophilia (WFH) humanitarian aid
program until 2030 and will donate at least 240 million international units (IU) of clotting factors (factor VIII
and factor IX) to the WFH Humanitarian Aid Program over the next eight years (2022-2030). According to the
WFH, this contribution will guarantee around 10,300 doses to treat approximately 3,000 patients a year in
developing countries, where access to adequate treatment is often lacking.
Following the renewal of this accord, Grifols will double its donation of clotting factors to the WFH,
building on the 440 million IU bestowed since 2014.
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
9
RISKS
At 30 June 2021 the Group’s financial risk management objectives and policies are consistent with those
disclosed in the consolidated financial statements for the year ended 31 December 2020.
Key financial metrics for the first half of 2021:
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
10
First half 2021 net revenue by division and region:
In thousands of euros 1H 2021 % of Net
Revenues 1H 2020 % of Net
Revenues % Var % Var cc*
BIOSCIENCE 1.986.024 78,3% 2.158.852 80,6% (8,0%) (0,1%)
DIAGNOSTIC 395.483 15,6% 340.012 12,7% 16,3% 22,9%
HOSPITAL 67.750 2,7% 57.863 2,2% 17,1% 19,5%
BIO SUPPLIES 107.260 4,2% 126.718 4,7% (15,4%) (8,5%)
OTHERS 15.488 0,6% 18.657 0,7% (17,0%) (11,5%)
INTERSEGMENTS (35.373) (1,4%) (24.761) (0,9%) 42,9% 51,7%
TOTAL 2.536.632 100,0% 2.677.341 100,0% (5,3%) 2,3%
In thousands of euros 1H 2021 % of Net
Revenues 1H 2020 % of Net
Revenues % Var % Var cc*
US + CANADA 1.576.893 62,2% 1.844.576 68,9% (14,5%) (6,1%)
EU 452.536 17,8% 376.442 14,1% 20,2% 20,5%
ROW 507.203 20,0% 456.323 17,0% 11,1% 21,3%
TOTAL 2.536.632 100,0% 2.677.341 100,0% (5,3%) 2,3%
* Constant currency (cc) excludes exchange rate fluctuations over the period.
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
11
Second quarter 2021 net revenues by division and region:
In thousands of euros 2Q 2021 % of Net
Revenues 2Q 2020 % of Net
Revenues % Var % Var cc*
BIOSCIENCE 1.084.747 80,2% 1.118.910 80,8% (3,1%) 5,1%
DIAGNOSTIC 192.214 14,2% 172.136 12,4% 11,7% 18,0%
HOSPITAL 36.543 2,7% 27.188 2,0% 34,4% 36,6%
BIO SUPPLIES 50.960 3,8% 62.579 4,5% (18,6%) (12,2%)
OTHERS 8.314 0,6% 13.513 1,0% (38,5%) (34,5%)
INTERSEGMENTS (20.880) (1,5%) (10.304) (0,7%) 102,6% 116,5%
TOTAL 1.351.898 100,0% 1.384.022 100,0% (2,3%) 5,3%
In thousands of euros 2Q 2021 % of Net
Revenues 2Q 2020 % of Net
Revenues % Var % Var cc*
US + CANADA 833.601 61,7% 932.425 67,4% (10,6%) (1,9%)
EU 220.598 16,3% 176.843 12,8% 24,7% 24,9%
ROW 297.699 22,0% 274.754 19,8% 8,4% 17,1%
TOTAL 1.351.898 100,0% 1.384.022 100,0% (2,3%) 5,3%
* Constant currency (cc) excludes exchange rate fluctuations over the period.
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
12
ANNEX - NON-GAAP (IFRS-EU) MEASURES RECONCILIATION
Net Revenues by division reported at constant currency for the first half of 2021:
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
13
Net Revenues by region reported at constant currency for the first half of 2021:
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
14
Reconciliation of other figures for the first half of 2021:
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
15
Group Adjusted Net Profit Reconciliation for the first half of 2021:
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
16
Net Revenues by division reported at constant currency for the first half of 2021:
|
|
GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Management Report
for the six-month period ended 30 June 2021
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail)
17
Net Revenues by region reported at constant currency for the second quarter of 2021:
“Cautionary Statement Regarding Forward-Looking Statements”
The facts and figures contained in this report that do not refer to historical data are “future projections and
assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”,
“should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to
the Grifols group, are used to identify future projections and assumptions. These expressions reflect the
assumptions, hypotheses, expectations and predictions of the management team at the time of writing this
report, and these are subject to a number of factors that mean that the actual results may be materially different.
The future results of the Grifols group could be affected by events relating to its own activities, such as a
shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products
on the market, or changes to the regulatory framework of the markets in which it operates, among others. At
the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential
impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future
projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report,
except where expressly required by the applicable legislation. This document does not constitute an offer or
invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation:
Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree
Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this
legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request
for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other
jurisdiction.
|